Our Borderplex community has a new pulmonary and critical care medicine specialist who plans to enhance lung disease screening protocols and programs to benefit patients and the future physicians who will care for them.

Sheldon Rao, M.D., is seeing patients at the Texas Tech Physicians of El Paso at Alberta clinic and has also joined the Texas Tech Health El Paso Department of Internal Medicine as an assistant professor.

Only a couple of centers and hospitals in El Paso County focus on critical respiratory care, the life-saving care for patients experiencing respiratory issues that cause trouble breathing. With over 800,000 living in El Paso County, Dr. Rao’s pulmonary and critical care skills will help underserved communities in need of his expertise.

“Pulmonary rehabilitation, when done appropriately, has an immense effect on survival, as well as the quality of life in people with end-stage lung disease,” Dr. Rao said. “I aim to introduce new technology and devices which can help those patients with lung disease.”

Before arriving at Texas Tech Health El Paso, Dr. Rao completed a pulmonary and critical care medicine fellowship at the Allegheny Health Network Medical Education Consortium in Pittsburgh, Pennsylvania, where he also completed his internal medicine residency. He received his bachelor’s degree in medicine from St. John’s Medical College in Bangalore, India.

Most of Dr. Rao’s research interests revolve around improving patients’ quality of life, and determining if the care they’re receiving improves the overall health of the community without being wasteful. He has published or co-published numerous journal articles and papers on timely pulmonary and critical care issues, including the challenges health care workers face when caring for COVID-19 patients, hematologic and oncologic emergencies in an intensive care setting, and asthma in pregnant women.

Dr. Rao wants to use his expertise to teach the next generation of health care professionals to meet our Borderplex region’s future needs. He’s created a curriculum about thoracic, or chest, ultrasounds and is working on upgrading lung cancer screening protocols and programs to mentor his students on how to detect and treat it early.

“I’m here to teach students and make patients more aware of the vast amount of therapeutics that await them in the pulmonary world, which has had massive advancements in the past five years,” Dr. Rao said.

To make an appointment with Dr. Rao, or any of our Texas Tech Physicians of El Paso, call 915-215-5200.

About Texas Tech Health El Paso

Texas Tech Health El Paso is the only health sciences center on the U.S.-Mexico border and serves 108 counties in West Texas that have been historically underserved. It’s a designated Title V Hispanic-Serving Institution, preparing the next generation of health care heroes, 48% of whom identify as Hispanic and are often first-generation students.

Established as an independent university in 2013, Texas Tech Health El Paso is a proudly diverse and uniquely innovative destination for education and research.

With a mission of eliminating health care barriers and creating life-changing educational opportunities for Borderplex residents, Texas Tech Health El Paso has graduated over 2,400 doctors, nurses and researchers over the past decade, and will add dentists to its alumni beginning in 2025. For more information, visit ttuhscepimpact.org.

About Texas Tech Physicians of El Paso

Texas Tech Physicians of El Paso is the clinical practice of the Foster School of Medicine. It’s the region’s largest multispecialty medical group practice, with over 250 specialists providing world-class patient care for the entire family at several locations across El Paso, while also providing a hands-on learning space for TTUHSC El Paso resident physicians and students.



Source link

Smoking was once considered to be a style statement in the form of cigars and hookahs as shown in various Hollywood and Bollywood movies. Though a statutory warning flashes with every such picture depicting smoking but unfortunately it is still increasing. The chemicals and toxins in tobacco smoke damage the delicate tissues of your lungs, leading to inflammation, irritation, and narrowing of the airways. Over time, this can cause permanent damage to the airways in your lungs, increasing your risk of developing serious lung disease.

by Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital
 
Smoking was once considered to be a style statement in the form of cigars and hookahs as shown in various Hollywood and Bollywood movies. Though a statutory warning flashes with every such picture depicting smoking but unfortunately it is still increasing. The chemicals and toxins in tobacco smoke damage the delicate tissues of your lungs, leading to inflammation, irritation, and narrowing of the airways. Over time, this can cause permanent damage to the airways in your lungs, increasing your risk of developing serious lung disease.
 
Air pollution also increases the risk of lung infections like bronchitis and pneumonia. In all the Metropolitan cities and urban areas, its residents grapple with unique challenges impacting lung health. The city's rapid urbanization brings forth concerning issues like air pollution, industrial emissions, and vehicular exhaust, all of which contribute to respiratory issues. Moreover, Bangalore's lush flora adds to the pollen levels, triggering allergies and exacerbating respiratory concerns. Seasonal variations in air quality and construction dust further compound these challenges, making lung health a pressing concern for its inhabitants.
 
Misconceptions Around Smoking and Lung Health
Recently No Smoking Day was observed and it is vital to address common misconceptions surrounding smoking and lung health. Many mistakenly believe that "light" or "low tar" cigarettes are less harmful, or perceive hookahs and e-cigarettes as safe alternatives. However, nicotine's addictive nature and smoking's comprehensive harm to the body, not just the lungs, must be acknowledged. Moreover, awareness about the irreversibility of smoking-induced lung damage remains low. We do not have to wait for ‘No Smoking Day’ to create awareness about the ill-health smoking can cause. It's crucial to emphasize that quitting smoking is pivotal for improving lung health and overall well-being. Support is available for those ready to embark on this journey towards a healthier life.
 
The Impact of Smoking on Lung Health Trends
Smoking remains a significant factor in the prevalence of lung diseases, including Chronic Obstructive Pulmonary Disease (COPD) and lung cancer, among Bangalore's residents. Both direct smokers and those exposed to second-hand smoke face increased risks, underscoring the pervasive threat smoking poses to lung health. Beyond quitting smoking, Bangalore residents can take proactive measures to safeguard their lung health. Regular exercise, a diet rich in antioxidants, and avoiding exposure to pollutants are paramount. Additionally, wearing masks during high pollution days, using air purifiers indoors, and scheduling regular health check-ups can mitigate pollution-related lung damage.
 
Improving Lung Health for Former Smokers
For individuals who have smoked previously, prioritizing lung health entails quitting smoking and engaging in pulmonary rehabilitation. Breathing exercises and vigilant avoidance of environments with air pollutants or second-hand smoke exposure are crucial for maintaining and improving lung function. To mitigate the adverse effects of air pollution, Bangalore residents should stay informed about air quality indices and limit outdoor activities during high pollution levels. Using N95 masks, improving indoor air quality, and advocating for cleaner energy sources are indispensable strategies.
 
Government Initiatives and Public Health Programs
The Government of India, through initiatives like the National Tobacco Control Program (NTCP), educates the public about smoking dangers. Bangalore, equipped with robust healthcare infrastructure, offers smoking cessation clinics providing counseling, medication, and support for individuals aiming to quit smoking.
 
Advancements in Lung Health Treatment and Prevention
Recent advancements, such as lung transplantation and personalized medicine, offer hope for improved lung health outcomes. Additionally, developments in pulmonary rehabilitation contribute to better preventive measures against chronic lung conditions like severe asthma. Research indicates a correlation between smoking and the severity of COVID-19 cases. Smokers are more likely to develop severe disease and experience worse outcomes due to lung damage and compromised immune function.
 
Resources for Smoking Cessation and Lung Health Awareness
Bangalore residents seeking to quit smoking or learn more about lung health can avail themselves of resources like the National Tobacco Cessation Program, QUITLINE, mobile cessation programs, local hospitals' smoking cessation clinics, online platforms, and community support groups. To conclude, prioritizing lung health requires collective efforts, including smoking cessation, pollution mitigation, and awareness campaigns. By taking proactive steps and leveraging available resources, Bangalore residents can safeguard their lung health and overall well-being.
 



Source link

Engineered stone, a popular choice for countertops, has proven
popular due to its aesthetic appeal, cost, durability, and
versatility. However, in recent years there has been focus on the
serious health concerns linked to engineered stone including
long-term respiratory illness and premature death. In this article,
we will delve into what engineered stone is, the serious
respiratory health problems it poses for workers, and the call for
the ban of its use in Australia.

What is engineered stone?

Engineered stone, often known by but not limited to brand names
like Caesarstone, Silestone, or Quantum Quartz, is a popular
material used for kitchen and bathroom countertops, as well as
other interior surfaces. It is made by combining crushed natural
stone, such as quartz, with polymer resins and pigments to create a
durable and attractive surface. The result is a versatile material
with a wide range of colours and patterns that mimics the look of
natural stone at a much cheaper cost, hence the popularity.

What exactly are the health risks linked to engineered
stone?

While engineered stone offers many advantages, there is a
notable downside associated with its production and fabrication.
Engineered stone contains a high concentration of crystalline
silica, a naturally occurring mineral found in quartz, which poses
a significant respiratory health risk when airborne. The fine dust
produced during the cutting, grinding, and polishing of engineered
stone surfaces can be inhaled by workers and lead to severe health
problems, including:

i. Silicosis
prolonged exposure to respirable crystalline silica dust can lead
to silicosis, an irreversible and often debilitating lung disease.
Silicosis causes scarring of lung tissue, leading to symptoms such
as coughing, breathlessness, and increased susceptibility to
respiratory infections. There is no cure for silicosis and if
developed, life expectancy is diminished.

ii. Lung cancer – inhaling
crystalline silica over an extended period is associated with an
increased risk of lung cancer. Most cases are not curable and
significantly reduce a worker's life expectancy.

iii. Chronic Obstructive Pulmonary Disease
(COPD)
silica exposure can
contribute to the development of COPD, a progressive lung condition
which includes emphysema and chronic bronchitis and is
characterised by breathing difficulties and shortness of
breath.

Silica dust exposure also increases the risk of developing
chronic kidney disease, autoimmune disorders (such as scleroderma
and systemic lupus erythematosus) and other adverse health effects,
including an increased risk of activating latent tuberculosis, eye
irritation and eye damage. The risk posed by engineered stone is
being touted as the new asbestos in terms of the
health ramifications for workers in Australia.

Legislative amendments to the Work Health and Safety Act 2011 (NSW) and
SafeWork Australia's call for a national ban

In response to growing concern over the health risks associated
with engineered stone, the NSW government has previously introduced
amendments to the Work Health and Safety Act 2011 (NSW)
which were designed to safeguard the health and well-being of
workers in the engineered stone industry.

These measures included reduced exposure limits, mandatory
health assessments, improved monitoring, and compliance as well as
education and training, and dust control measures which required
employers to implement effective dust control measures, including
proper ventilation, wet cutting methods, and the use of suitable
personal protective equipment.

To date however, persons conducting a business in this industry,
workers and regulators have failed to ensure the health and safety
of all workers working with engineered stone. In particular, the
lack of effective monitoring and compliance, despite some smaller
and sporadic wins, remains a big issue within the industry.

SafeWork Australia (SWA) has called for a
complete ban of the use of engineered stone in Australia. It has
undertaken significant work since 2018 to improve WHS arrangements
to prevent dust diseases including silicosis. This has included
amendments to NSW WHS legislation, however in February 2023 WHS
ministers agreed to SWA's recommendations to address workplace
exposure to respirable crystalline silica through national
awareness and change in behaviour initiatives, and further
regulation for all materials across all industries (which includes
engineered stone).

SWA undertook extensive analysis and consultation on the impacts
of a prohibition on the use of engineered stone and provided its
decision in a report to WHS Ministers on 16 August 2023 for
their consideration. The expert analysis undertaken shows that dust
from engineered stone poses unique hazards, and there is no
evidence that lower silica engineered stone is safer to work with,
meaning there is no safe level of exposure for workers. SWA has
recommended a prohibition on the use of all engineered stone,
irrespective of the crystalline silica content. There is also a
recommendation of the introduction of a licensing scheme to ensure
appropriate controls are in place to protect worker health when
engineered stone already in place needs to be removed, repaired, or
modified.

Silicosis and dust diseases pose an unacceptable health risk to
workers in Australia, and it is important to note that there are
significant financial and non-financial costs associated with being
diagnosed with silicosis or a dust disease, including significant
physical and emotional harm, the reduced ability to work, reduced
quality of life and ultimately premature death of workers. There
are also significant costs to the public health system and in turn
our economy.

SWA recommends urgent government intervention, due to the
disproportionate number of silicosis cases in engineered stone
workers, the younger age of diagnosis of silicosis and dust related
diseases in engineered stone workers, and the impacts on workers,
their families, and the wider community. The decision to prohibit
the use of some or all engineered stone is a matter for WHS
ministers who will meet later this year. It is clear that while
engineered stone revolutionised interior design, the long-term
health risks for workers involved in its fabrication and
installation outweighs the gain.

The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.

Source link

  • James SLAD, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–858.

    Article 

    Google Scholar
     

  • Mattila T, Vasankari T, Kauppi P, Mazur W, Härkänen T, Heliövaara M. Mortality of asthma, COPD, and asthma-COPD overlap during an 18 year follow up. Respir Med. 2023;207: 107112.

    Article 
    PubMed 

    Google Scholar
     

  • Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709–21.

    Article 
    PubMed 

    Google Scholar
     

  • Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Marcon A, Locatelli F, Dharmage SC, Svanes C, Heinrich J, Leynaert B, et al. The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories. Eur Respir J. 2021. doi.org/10.1183/13993003.04656-2020.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Slats A, Taube C. Asthma and chronic obstructive pulmonary disease overlap: asthmatic chronic obstructive pulmonary disease or chronic obstructive asthma? Ther Adv Respir Dis. 2016;10(1):57–71.

    Article 
    PubMed 

    Google Scholar
     

  • Çolak Y. Undiagnosed (or unrecognised) COPD and asthma: does active case-finding identify clinically impaired patients with treatment potential. Am J Respir Crit Care Med. 2023. doi.org/10.1164/rccm.202310-1793ED.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med. 2017;5(5):426–34.

    Article 
    PubMed 

    Google Scholar
     

  • Dasgupta S, Ghosh N, Bhattacharyya P, Roy Chowdhury S, Chaudhury K. Metabolomics of asthma, COPD, and asthma-COPD overlap: an overview. Crit Rev Clin Lab Sci. 2023;60(2):153–70.

    Article 
    PubMed 

    Google Scholar
     

  • Kelly RS, Dahlin A, McGeachie MJ, Qiu W, Sordillo J, Wan ES, et al. Asthma metabolomics and the potential for integrative omics in research and the clinic. Chest. 2017;151(2):262–77.

    Article 
    PubMed 

    Google Scholar
     

  • Terracciano R, Preianò M, Palladino GP, Carpagnano GE, Barbaro MP, Pelaia G, et al. Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases. Proteomics. 2011;11(16):3402–14.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pelaia G, Terracciano R, Vatrella A, Gallelli L, Busceti MT, Calabrese C, Stellato C, Savino R, Maselli R. Application of proteomics and peptidomics to COPD. Biomed Res Int. 2014;2014: 764581.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gao D, Zhang L, Song D, Lv J, Wang L, Zhou S, et al. Values of integration between lipidomics and clinical phenomes in patients with acute lung infection, pulmonary embolism, or acute exacerbation of chronic pulmonary diseases: a preliminary study. J Transl Med. 2019;17(1):162.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):132.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen L, Lu W, Wang L, Xing X, Chen Z, Teng X, et al. Metabolite discovery through global annotation of untargeted metabolomics data. Nat Method. 2021;18(11):1377–85.

    Article 

    Google Scholar
     

  • Luan H, Gu W, Li H, Wang Z, Lu L, Ke M, et al. Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients. J Transl Med. 2021;19(1):500.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang R, Li B, Lam SM, Shui G. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression. J Genet Genom. 2020;47(2):69–83.

    Article 
    CAS 

    Google Scholar
     

  • Correnti S, Preianò M, Fregola A, Gamboni F, Stephenson D, Savino R, et al. Seminal plasma untargeted metabolomic and lipidomic profiling for the identification of a novel panel of biomarkers and therapeutic targets related to male infertility. Front Pharmacol. 2023;14:1275832.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liang Y, Gai XY, Chang C, Zhang X, Wang J, Li TT. Metabolomic profiling differences among asthma, COPD, and healthy subjects: A LC-MS-based metabolomic analysis. Biomed Environ Sci. 2019;32(9):659–72.

    CAS 
    PubMed 

    Google Scholar
     

  • Adamko DJ, Nair P, Mayers I, Tsuyuki RT, Regush S, Rowe BH. Metabolomic profiling of asthma and chronic obstructive pulmonary disease: a pilot study differentiating diseases. J Allerg Clin Immunol. 2015;136(3):571-80.e3.

    Article 

    Google Scholar
     

  • Khamis MM, Holt T, Awad H, El-Aneed A, Adamko DJ. Comparative analysis of creatinine and osmolality as urine normalization strategies in targeted metabolomics for the differential diagnosis of asthma and COPD. Metabolomics. 2018;14(9):115.

    Article 
    PubMed 

    Google Scholar
     

  • D’Amato M, Iadarola P, Viglio S. Proteomic analysis of human sputum for the diagnosis of lung disorders: where are we today? Int J Mol Sci. 2022. doi.org/10.3390/ijms23105692.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Global Strategy for Asthma Management and Prevention. ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed on 14 December 2023.

  • Global Strategy for Prevention, Diagnosis and Management of COPD. goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf. Accessed on 14 December 2023.

  • Nemkov T, Reisz JA, Gehrke S, Hansen KC, D’Alessandro A. High-throughput metabolomics: isocratic and gradient mass spectrometry-based methods. Method Mol Biol. 2019;1978:13–26.

    Article 
    CAS 

    Google Scholar
     

  • Reisz JA, Zheng C, D’Alessandro A, Nemkov T. Untargeted and semi-targeted lipid analysis of biological samples using mass spectrometry-based metabolomics. Method Mol Biol. 2019;1978:121–35.

    Article 
    CAS 

    Google Scholar
     

  • Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci. 2017;131(13):1541–58.

    Article 
    CAS 

    Google Scholar
     

  • Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm Pharmacol Ther. 2013;26(6):710–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Nickler M, Ottiger M, Steuer C, Huber A, Anderson JB, Müller B, et al. Systematic review regarding metabolic profiling for improved pathophysiological understanding of disease and outcome prediction in respiratory infections. Respir Res. 2015;16:125.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sim S, Choi Y, Park HS. Potential metabolic biomarkers in adult asthmatics. Metabolites. 2021. doi.org/10.3390/metabo11070430.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pulik K, Mycroft K, Korczyński P, Ciechanowicz AK, Górska K. Metabolomic analysis of respiratory epithelial lining fluid in patients with chronic obstructive pulmonary disease—a systematic review. Cells. 2023. doi.org/10.3390/cells12060833.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sinha A, Desiraju K, Aggarwal K, Kutum R, Roy S, Lodha R, et al. Exhaled breath condensate metabolome clusters for endotype discovery in asthma. J Transl Med. 2017;15(1):262.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ravi A, Goorsenberg AWM, Dijkhuis A, Dierdorp BS, Dekker T, van Weeghel M, et al. Metabolic differences between bronchial epithelium from healthy individuals and patients with asthma and the effect of bronchial thermoplasty. J Allerg Clin Immunol. 2021;148(5):1236–48.

    Article 
    CAS 

    Google Scholar
     

  • Maniscalco M, Paris D, Melck DJ, Molino A, Carone M, Ruggeri P, et al. Differential diagnosis between newly diagnosed asthma and COPD using exhaled breath condensate metabolomics: a pilot study. Eur Respir J. 2018;51(3):1701825.

    Article 
    PubMed 

    Google Scholar
     

  • Fens N, Roldaan AC, van der Schee MP, Boksem RJ, Zwinderman AH, Bel EH, et al. External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease. Clin Exp Allerg. 2011;41(10):1371–8.

    Article 
    CAS 

    Google Scholar
     

  • Jiang T, Dai L, Li P, Zhao J, Wang X, An L, et al. Lipid metabolism and identification of biomarkers in asthma by lipidomic analysis. Biochim Biophys Acta Mol Cell Biol Lipid. 2021;1866(2): 158853.

    Article 
    CAS 

    Google Scholar
     

  • Ntontsi P, Ntzoumanika V, Loukides S, Benaki D, Gkikas E, Mikros E, et al. EBC metabolomics for asthma severity. J Breath Res. 2020;14(3): 036007.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ried JS, Baurecht H, Stückler F, Krumsiek J, Gieger C, Heinrich J, et al. Integrative genetic and metabolite profiling analysis suggests altered phosphatidylcholine metabolism in asthma. Allergy. 2013;68(5):629–36.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tian M, Chen M, Bao YL, Xu CD, Qin QZ, Zhang WX, et al. Sputum metabolomic profiling of bronchial asthma based on quadruple time-of-flight mass spectrometry. Int J Clin Exp Pathol. 2017;10(10):10363–73.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Quinn KD, Schedel M, Nkrumah-Elie Y, Joetham A, Armstrong M, Cruickshank-Quinn C, et al. Dysregulation of metabolic pathways in a mouse model of allergic asthma. Allergy. 2017;72(9):1327–37.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ran N, Pang Z, Gu Y, Pan H, Zuo X, Guan X, et al. An updated overview of metabolomic profile changes in chronic obstructive pulmonary disease. Metabolites. 2019;9(6):111.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pacheco-Alvarez D, Solórzano-Vargas RS, Del Río AL. Biotin in metabolism and its relationship to human disease. Arch Med Res. 2002;33(5):439–47.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. Biochem J. 2002;361(Pt 3):417–29.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Halper-Stromberg E, Gillenwater L, Cruickshank-Quinn C, O’Neal WK, Reisdorph N, Petrache I, et al. Bronchoalveolar lavage Fluid from COPD patients reveals more compounds associated with disease than matched plasma. Metabolites. 2019;9(8):157.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cruickshank-Quinn CI, Jacobson S, Hughes G, Powell RL, Petrache I, Kechris K, et al. Metabolomics and transcriptomics pathway approach reveals outcome-specific perturbations in COPD. Sci Rep. 2018;8(1):17132.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ghosh N, Choudhury P, Subramani E, Saha D, Sengupta S, Joshi M, et al. Metabolomic signatures of asthma-COPD overlap (ACO) are different from asthma and COPD. Metabolomics. 2019;15(6):87.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sagar NA, Tarafdar S, Agarwal S, Tarafdar A, Sharma S. Polyamines: functions, metabolism, and role in human disease management. Med Sci. 2021;9(2):44.

    CAS 

    Google Scholar
     

  • Jain V. Role of polyamines in asthma pathophysiology. Med Sci. 2018;6(1):4.


    Google Scholar
     

  • Hoet PH, Nemery B. Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions. Am J Physiol Lung Cell Mol Physiol. 2000;278(3):L417-33.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kurosawa M, Shimizu Y, Tsukagoshi H, Ueki M. Elevated levels of peripheral-blood, naturally occurring aliphatic polyamines in bronchial asthmatic patients with active symptoms. Allergy. 1992;47(6):638–43.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zimmermann N, King NE, Laporte J, Yang M, Mishra A, Pope SM, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest. 2003;111(12):1863–74.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kurosawa M, Uno D, Kobayashi S. Naturally occurring aliphatic polyamines-induced histamine release from rat peritoneal mast cells. Allerg. 1991;46(5):349–54.

    Article 
    CAS 

    Google Scholar
     

  • Ilmarinen P, Moilanen E, Erjefält JS, Kankaanranta H. The polyamine spermine promotes survival and activation of human eosinophils. J Allerg Clin Immunol. 2015;136(2):482-4.e11.

    Article 
    CAS 

    Google Scholar
     

  • North ML, Grasemann H, Khanna N, Inman MD, Gauvreau GM, Scott JA. Increased ornithine-derived polyamines cause airway hyperresponsiveness in a mouse model of asthma. Am J Respir Cell Mol Biol. 2013;48(6):694–702.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zuo L, Koozechian MS, Chen LL. Characterization of reactive nitrogen species in allergic asthma. Ann Allerg Asthma Immunol. 2014;112(1):18–22.

    Article 
    CAS 

    Google Scholar
     

  • Ghosh S, Erzurum SC. Nitric oxide metabolism in asthma pathophysiology. Biochim Biophys Acta. 2011;1810(11):1008–16.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Maarsingh H, Leusink J, Zaagsma J, Meurs H. Role of the l-citrulline/l-arginine cycle in iNANC nerve-mediated nitric oxide production and airway smooth muscle relaxation in allergic asthma. Eur J Pharmacol. 2006;546(1–3):171–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40(3):235–43.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Rajendiran E, Ramadass B, Ramprasath V. Understanding connections and roles of gut microbiome in cardiovascular diseases. Can J Microbiol. 2021;67(2):101–11.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Enaud R, Prevel R, Ciarlo E, Beaufils F, Wieërs G, Guery B, et al. The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks. Front Cell Infect Microbiol. 2020;10:9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Anand S, Mande SS. Diet, Microbiota and Gut-Lung Connection. Front Microbiol. 2018;9:2147.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ghorbani P, Santhakumar P, Hu Q, Djiadeu P, Wolever TM, Palaniyar N, et al. Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. Eur Respir J. 2015;46(4):1033–45.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Liu Q, Tian X, Maruyama D, Arjomandi M, Prakash A. Lung immune tone via gut-lung axis: gut-derived LPS and short-chain fatty acids’ immunometabolic regulation of lung IL-1β, FFAR2, and FFAR3 expression. Am J Physiol Lung Cell Mol Physiol. 2021;321(1):L65-l78.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yoon HJ, Park MK, Lee H, Park TS, Park DW, Moon JY, et al. Effects of respiratory short-chain fatty acids on bronchial inflammation in asthma. World Allerg Organ J. 2020;13(8):100204.

    Article 

    Google Scholar
     

  • Richards LB, Li M, Folkerts G, Henricks PAJ, Garssen J, van Esch B. Butyrate and propionate restore the cytokine and house dust mite compromised barrier function of human bronchial airway epithelial cells. Int J Mol Sci. 2020;22(1):65.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tatsuta M, Kan OK, Ishii Y, Yamamoto N, Ogawa T, Fukuyama S, et al. Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37. Respir Res. 2019;20(1):251.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li N, Dai Z, Wang Z, Deng Z, Zhang J, Pu J, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respir Res. 2021;22(1):274.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li C, Zhao H. Tryptophan and its metabolites in lung cancer: basic functions and clinical significance. Front Oncol. 2021;11: 707277.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Naz S, Bhat M, Ståhl S, Forsslund H, Sköld CM, Wheelock ÅM, et al. Dysregulation of the tryptophan pathway evidences gender differences in COPD. Metabolites. 2019;9(10):212.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gulcev M, Reilly C, Griffin TJ, Broeckling CD, Sandri BJ, Witthuhn BA, et al. Tryptophan catabolism in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2435–46.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762–74.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Yan Z, Chen B, Yang Y, Yi X, Wei M, Ecklu-Mensah G, et al. Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions. Nat Microbiol. 2022;7(9):1361–75.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8(12):3125–33.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Maneechotesuwan K, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD. Thorax. 2013;68(4):330–7.

    Article 
    PubMed 

    Google Scholar
     

  • Liu H, Liu L, Fletcher BS, Visner GA. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med. 2006;173(5):566–72.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Reyes Ocampo J, Lugo Huitrón R, González-Esquivel D, Ugalde-Muñiz P, Jiménez-Anguiano A, Pineda B, et al. Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases. Oxid Med Cell Longev. 2014;2014: 646909.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Savonije K, Weaver DF. The role of tryptophan metabolism in alzheimer’s disease. Brain Sci. 2023;13(2):292.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sorgdrager FJH, Naudé PJW, Kema IP, Nollen EA, Deyn PP. Tryptophan metabolism in inflammaging from biomarker to therapeutic target. Front Immunol. 2019;10:2565.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kalantar-Zadeh K, Ganz T, Trumbo H, Seid MH, Goodnough LT, Levine MA. Parenteral iron therapy and phosphorus homeostasis: a review. Am J Hematol. 2021;96(5):606–16.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li S, Huang Q, Nan W, He B. Association between serum phosphate and in-hospital mortality of patients with AECOPD: a retrospective analysis on eICU database. Heliyon. 2023;9(9): e19748.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jung SY, Kwon J, Park S, Jhee JH, Yun HR, Kim H, et al. Phosphate is a potential biomarker of disease severity and predicts adverse outcomes in acute kidney injury patients undergoing continuous renal replacement therapy. PLoS ONE. 2018;13(2): e0191290.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Xu H, Evans M, Gasparini A, Szummer K, Spaak J, Ärnlöv J, et al. Outcomes associated to serum phosphate levels in patients with suspected acute coronary syndrome. Int J Cardiol. 2017;245:20–6.

    Article 
    PubMed 

    Google Scholar
     

  • Stroda A, Brandenburg V, Daher A, Cornelissen C, Goettsch C, Keszei A, et al. Serum phosphate and phosphate-regulatory hormones in COPD patients. Respir Res. 2018;19(1):183.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Farah R, Khamisy-Farah R, Arraf Z, Jacobson L, Makhoul N. Hypophosphatemia as a prognostic value in acute exacerbation of COPD. Clin Respir J. 2013;7(4):407–15.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Campos-Obando N, Lahousse L, Brusselle G, Stricker BH, Hofman A, Franco OH, et al. Serum phosphate levels are related to all-cause, cardiovascular and COPD mortality in men. Eur J Epidemiol. 2018;33(9):859–71.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Giraud MF, Naismith JH. The rhamnose pathway. Curr Opin Struct Biol. 2000;10(6):687–96.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Melamed J, Kocev A, Torgov V, Veselovsky V, Brockhausen I. Biosynthesis of the Pseudomonas aeruginosa common polysaccharide antigen by d-Rhamnosyltransferases WbpX and WbpY. Glycoconj J. 2022;39(3):393–11.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Eklöf J, Sørensen R, Ingebrigtsen TS, Sivapalan P, Achir I, Boel JB, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020;26(2):227–34.

    Article 
    PubMed 

    Google Scholar
     

  • Jacobs DM, Ochs-Balcom HM, Noyes K, Zhao J, Leung WY, Pu CY, et al. Impact of pseudomonas aeruginosa isolation on mortality and outcomes in an outpatient chronic obstructive pulmonary disease cohort. Open Forum Infect Dis. 2020;7(1):ofz546.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang Q, Illing R, Hui CK, Downey K, Carr D, Stearn M, et al. Bacteria in sputum of stable severe asthma and increased airway wall thickness. Respir Res. 2012;13(1):35.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Garcia-Clemente M, de la Rosa D, Máiz L, Girón R, Blanco M, Olveira C, et al. Impact of pseudomonas aeruginosa infection on patients with chronic inflammatory airway diseases. J Clin Med. 2020;9(12):3800.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kayongo A, Robertson NM, Siddharthan T, Ntayi ML, Ndawula JC, Sande OJ, et al. Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease. Front Immunol. 2022;13:1085551.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mander A, Langton-Hewer S, Bernhard W, Warner JO, Postle AD. Altered phospholipid composition and aggregate structure of lung surfactant is associated with impaired lung function in young children with respiratory infections. Am J Respir Cell Mol Biol. 2002;27(6):714–21.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Telenga ED, Hoffmann RF, Ruben tK, Hoonhorst SJ, Willemse BW, van Oosterhout AJ, et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease uncovering sphingolipids. Am J Respir Crit Care Med. 2014;190(2):155–64.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chen H, Li Z, Dong L, Wu Y, Shen H, Chen Z. Lipid metabolism in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:1009–18.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gai X, Guo C, Zhang L, Zhang L, Abulikemu M, Wang J, et al. Serum glycerophospholipid profile in acute exacerbation of chronic obstructive pulmonary disease. Front Physiol. 2021;12: 646010.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kilk K, Aug A, Ottas A, Soomets U, Altraja S, Altraja A. Phenotyping of chronic obstructive pulmonary disease based on the integration of metabolomes and clinical characteristics. Int J Mol Sci. 2018;19(3):666.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kang YP, Lee WJ, Hong JY, Lee SB, Park JH, Kim D, et al. Novel approach for analysis of bronchoalveolar lavage fluid (BALF) using HPLC-QTOF-MS-based lipidomics: lipid levels in asthmatics and corticosteroid-treated asthmatic patients. J Proteome Res. 2014;13(9):3919–29.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Liu X, Zhang H, Si Y, Du Y, Wu J, Li J. High-coverage lipidomics analysis reveals biomarkers for diagnosis of acute exacerbation of chronic obstructive pulmonary disease. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1201–1202: 123278.

    Article 
    PubMed 

    Google Scholar
     

  • Agudelo CW, Kumley BK, Area-Gomez E, Xu Y, Dabo AJ, Geraghty P, et al. Decreased surfactant lipids correlate with lung function in chronic obstructive pulmonary disease (COPD). PLoS ONE. 2020;15(2): e0228279.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139–50.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kim J, Suresh B, Lim MN, Hong SH, Kim KS, Song HE, et al. Metabolomics reveals dysregulated sphingolipid and amino acid metabolism associated with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2022;17:2343–53.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 2011;5(5):325–44.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bowler RP, Jacobson S, Cruickshank C, Hughes GJ, Siska C, Ory DS, et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med. 2015;191(3):275–84.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • McCann MR, George De la Rosa MV, Rosania GR, Stringer KA. l-Carnitine and acylcarnitines: mitochondrial biomarkers for precision medicine. Metabolites. 2021;11(1):51.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gillenwater LA, Kechris KJ, Pratte KA, Reisdorph N, Petrache I, Labaki WW, et al. Metabolomic profiling reveals sex specific associations with chronic obstructive pulmonary disease and emphysema. Metabolites. 2021;11(3):161.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Callejón-Leblic B, Pereira-Vega A, Vázquez-Gandullo E, Sánchez-Ramos JL, Gómez-Ariza JL, García-Barrera T. Study of the metabolomic relationship between lung cancer and chronic obstructive pulmonary disease based on direct infusion mass spectrometry. Biochimie. 2019;157:111–22.

    Article 
    PubMed 

    Google Scholar
     

  • Kim DJ, Oh JY, Rhee CK, Park SJ, Shim JJ, Cho JY. Metabolic fingerprinting uncovers the distinction between the phenotypes of tuberculosis associated COPD and smoking-induced COPD. Front Med. 2021;8: 619077.

    Article 

    Google Scholar
     

  • Naz S, Kolmert J, Yang M, Reinke SN, Kamleh MA, Snowden S, et al. Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD. Eur Respir J. 2017;49(6):1602322.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yu B, Flexeder C, McGarrah RW 3rd, Wyss A, Morrison AC, North KE, et al. Metabolomics identifies novel blood biomarkers of pulmonary function and COPD in the general population. Metabolites. 2019;9(4):61.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lommatzsch M, Cicko S, Müller T, Lucattelli M, Bratke K, Stoll P, et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(9):928–34.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 2007;13(8):913–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med. 2009;361(27):2599–608.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Reinke SN, Naz S, Chaleckis R, Gallart-Ayala H, Kolmert J, Kermani NZ, et al. Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. Eur Respir J. 2022;59(6):2101733.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Terracciano R, Pelaia G, Preianò M, Savino R. Asthma and COPD proteomics: current approaches and future directions. Proteom Clin Appl. 2015;9(1–2):203–20.

    Article 
    CAS 

    Google Scholar
     

  • Source link

    (MENAFN- Straits Research) Respiratory disposables connect respiratory equipment like ventilators, nebulizers, and oxygen therapy devices. Respiratory disposables include disposable oxygen masks, disposable resuscitators, and disposable tubes. Healthcare workers wear disposable respiratory protective equipment during procedures to prevent them from spreading microorganisms, bodily fluids, and foreign particles. Treatment for respiratory conditions like asthma, sleep apnea, and chronic obstructive pulmonary disease is provided by respiratory disposables (COPD). In addition to preventing infections, they also lessen the financial strain on hospitals, save time, and boost demand.
    Market Dynamics
    Increasing Respiratory Illnesses Drive the Global Market
    In the coming years, it is projected that an increase in the incidence of respiratory diseases that impact the respiratory system will help the sector flourish. There will be 38% more cases of lung cancer worldwide by 2030. The substantial rise in the prevalence of respiratory disorders is also projected to drive up the price of respiratory disposables. Due to the anticipated increase in the prevalence of respiratory diseases, including asthma and COPD, the global market for respiratory disposables is expected to expand.
    Rising Number of Viruses Attacking the Respiratory System Creates Tremendous Opportunities
    Respiratory viruses are people's most frequent disease-inducing agents and have a significant global impact on morbidity and mortality. Common respiratory pathogens from different virus families are well-suited for efficient person-to-person transmission worldwide. The respiratory viruses that circulate most frequently as endemic or epidemic agents include the influenza virus, respiratory syncytial virus, parainfluenza viruses, metapneumovirus, rhinovirus, coronavirus, adenovirus, and bocavirus. The market for respiratory disposables is expected to increase significantly due to the outbreak of these viruses because these products help to prevent the transmission of infections from one person to another.
    Regional Analysis
    North America is the most significant shareholder in the global respiratory disposables market and is expected to grow at a CAGR of 9.3% during the forecast period. North America has a sizable growth opportunity due to the government's focus on improving the healthcare infrastructure. The U.S. gained the highest revenue share due to the rising demand for maintaining a higher standard of living, the availability of skilled workers, and significant market players. The prevalence of state-of-the-art healthcare facilities with qualified medical staff, rising disposable demand for respiratory products, and increasing incidences of respiratory diseases like lung cancer, asthma, and COPD all contribute significantly to North America's market growth.
    Europe is expected to grow at a CAGR of 9.5% generating USD 989.82 million during the forecast period. During the forecast period, the respiratory disposables market in European countries is anticipated to grow steadily due to consumer demand for better respiratory disposables and the substantial presence of key players like Medtronic Plc. and Air Liquide S.A. A rise in the prevalence of respiratory diseases, an increase in air pollution, and new product developments in respiratory disposables are also significant growth drivers in Europe. The availability of qualified professionals and the development of the healthcare infrastructure are two additional key growth drivers for the Europe respiratory disposables market.
    Key Highlights

    The global respiratory disposables market was valued at USD 1.49 billion in 2021. It is projected to reach USD 3.4 billion by 2030, growing at a CAGR of 9.6 % during the forecast period (2022–2030).
    Based on product, the global respiratory disposables market is bifurcated into laryngoscopes, tubes, breathing bags, masks, resuscitators, and others. The resuscitators segment is the highest contributor to the market and is expected to grow at a CAGR of 8.9% during the forecast period.
    Based on patient groups, the global respiratory disposables market is bifurcated into neonatal and pediatric, adult, and geriatric. The geriatric segment owns the highest market share and is expected to grow at a CAGR of 9.4% during the forecast period.
    Based on end-user, the global respiratory disposables market is bifurcated into hospitals, nursing homes, and clinics, trauma centers, and home care. The hospitals, nursing homes, and clinics segment is the highest contributor to the market and is expected to grow at a CAGR of 9.1% during the forecast period.
    North America is the most significant shareholder in the global respiratory disposables market and is expected to grow at a CAGR of 9.3% during the forecast period.

    Competitive Players
    The global respiratory disposables market's major key players are 3M, Air Liquide S.A., Allied Healthcare Products Inc., Ambu S/A, B. Braun SE, Chart Industries Inc, Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Corporation Limited, General Electric., Getinge AB, Hamilton Medical, Invacare Corporation, Koninklijke Philips N.V., Medtronic, Masimo Corporation, ResMed, Rotech Healthcare Inc., Smiths Group plc., and SunMed, Teleflex Incorporated.
    Market News

    In October 2022, Hamilton Medical offered comfort to patients with an NIV mask portfolio. For patients, Hamilton Medical and Pulmodyne partnered to offer various interfaces.
    In August 2022, ResMed pledged to invest EUR 30 million in Irish research and development. According to a ResMed study, COPD is the third-deadliest disease in the world and affects over 480 million people.

    Global
    Respiratory Disposables
    Market: Segmentation
    By Product

    Laryngoscope
    Tubes
    Breathing Bag
    Masks
    Resuscitator
    Others

    By Patient Group

    Neonatal and Pediatric
    Adult
    Geriatric

    By End-User

    Hospitals, Nursing Homes, and Clinics
    Trauma Centers
    Homecare

    By Regions

    North America
    Europe
    Asia-Pacific
    LAMEA

    MENAFN22032024004597010339ID1108010658


    Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

    Source link

    Nurse Teresa Giamboy, administrative director for Jefferson Health Northeast, spoke at last week’s East Torresdale Civic Association meeting, specifically addressing Jefferson Torresdale’s advanced lung care program.

    Giamboy told the crowd that insurance covers lung care screenings for people ages 50-80 who are current or former smokers and show no signs or symptoms of lung cancer.

    Nine out of 10 cases of lung cancer are related to tobacco, Giamboy said. The rest are related to genetics and the workplace, she added.

    Giamboy said smoking rates are down, but lung cancer rates have not dropped, attributing this to environmental reasons. She also said vaping is more dangerous than smoking, adding that recreational pot smoking can increase the chance of developing lung cancer.

    Jefferson offers pulmonary rehabilitation, a lung module clinic, a robotic bronchoscopy program, robotic thoracic surgery and a minimally invasive procedure to improve breathing.

    Call 215-890-SKCC.

    In other news from the March 11 meeting:

    • State Sen. Jimmy Dillon addressed the crowd, giving his background as a graduate of Our Lady of Calvary, Holy Ghost Prep (class of 1996) and Notre Dame.

    “I’m all about Northeast Philly,” he said.

    He’s Democratic leader of Ward 66-A, a position formerly held by his dad and brother. For 17 years, he’s operated the Hoops 24-7 Basketball Academy, a clinic and player development program.

    Among his top issues are safety, quality of life and addressing the lack of police manpower. He has spoken to Gov. Josh Shapiro about the old building and trailers used as offices at the Fire Academy.

    The senator will hold a senior expo on March 28 from 10 a.m. to 1 p.m. at MaST Community Charter School III, 1 Crown Way. Call 215-281-2539 or email [email protected].

    Dillon’s office at 12361 Academy Road has a representative from the Veterans Multi-Service Center on the second Tuesday of the month from 9 a.m. to 2 p.m.

    • ETCA approved, 18-8, a variance for a vehicle repair and maintenance shop at 9901 Frankford Ave., the former home of a 7-Eleven and a kitchen and bath store. There will be four bays. Hours will be 8 a.m. to 6 p.m, Monday through Saturday. A Zoning Board of Adjustment hearing will be on March 27.

    • Nazareth Academy senior Bridget Olsen, a Torresdale resident, earned a full, four-year scholarship to Holy Family. She will study nursing. She was chosen based on academics and community involvement. The scholarship is part of a community benefits agreement among the Upper Holmesburg Civic Association, Holy Family and NewCourtland, for redevelopment of the former Liddonfield Homes housing project.

    • The office of City Councilman Mike Driscoll can provide information on Veterans Affairs and Medicare issues. Call 215-683-9920.

    • Some residents complained that nothing is being done about large puddles that form on Grant Avenue, near the Torresdale Train Station, after rainfall.

    • East Torresdale Civic Association will meet on Monday, April 1, at 7 p.m. at All Saints’ Episcopal Church, 9601 Frankford Ave. The meeting after that will be on May 13, when the group will hold its annual cookie and baking contest. ••

    Source link

    March 19, 2024

    By Xari Jalil


    LAHORE

    In IQAir’s annual World Air Quality Report 2023 released today Pakistan has emerged as the second most polluted country in the world.

    The report has revealed that the annual average particulate matter (PM2.5) concentration is 14 times higher than the guidelines given by the World Health Organization at 73.7 μg/m³, which has impacted the quality and expectancy of life. A loss in life expectancy of 4.4 years across Pakistan has been calculated by the Pakistan Air Quality Initiative (PAQI).

    Lahore – fifth most polluted city

    Aside from being in the top most polluted countries, Pakistan also has the ill repute of having one of its mega city Lahore as being on the list of the top most polluted cities in the world – on the 5th position. Lahore’s pollution levels have been measured at 99.5 μg/m³, 20 times higher than WHO  guidelines for exposure to fine particulate level pollution. Pollution levels in Lahore are even worse than New Delhi which is 92.7 μg/m³.

    Lahore residents are facing a serious health threat, according to data from Punjab’s Environmental Protection Department. Their readings show alarming levels of hazardous air pollution, averaging 108 μg/m³. This is significantly higher than safe limits, and the situation worsens during the smog season. In November, the average pollution level skyrocketed to a staggering 251 μg/m³. These figures highlight the urgent need for immediate action to address Lahore’s air quality crisis.

    Dr Saima Saeed, Head of Pulmonology & Director, Lung Health Program, Indus Hospital and Health Network has stated that the air pollution contributes to multiple health issues all year long.

    “This level of air pollution causes chest infections and lung cancer as well as worsening lung diseases such as asthma and chronic obstructive pulmonary disease (COPD)” she said. “Pakistan’s poor air quality makes other non-communicable diseases such as strokes, mental health issues and diabetes more likely. Air pollution is also known to affect fertility and the cognitive development of children.”

    Other Cities

    The top worst polluted cities in Pakistan are Lahore (99.5), Faisalabad (88.2), Peshawar (76.5), Rawalpindi (59.5), Karachi (56.4) and Islamabad (42.4).

    Part of the data in this report is by on-ground measurements by the Pakistan Air Quality Initiative (PAQI), which has deployed a number of monitoring stations since 2016. These fill a significant gap in government-operated regulatory monitoring of air pollution, which are mandated to monitor and report a number of criteria pollutants to the public.

    “Islamabad has gone up from 17th place to 9th in the list of most polluted capitals in the world, while Pakistan has been ranked as the 2nd most polluted country for the first time after being 3rd consistently,” according to Dawar Hameed, Chief Executive Officer of PAQI. 

    “All of this has happened at a time when the economy is weak and overall activities are lower than previous years. These indicators are showing that poor air quality is a crisis that has minimal attention from successive governments, and consequently turned into a daunting public health crisis.”

    Particulate matter pollution is especially dangerous for health as it can penetrate through lung tissue and enter into the bloodstream. Other pollutants include carbon monoxide, nitrogen oxides and sulfur oxides, which should also be monitored and regulated to be within safe limits. 

    “A clean, healthy, and sustainable environment is a universal human right. In many parts of the world the lack of air quality data delays decisive action and perpetuates unnecessary human suffering. Air quality data saves lives. Where air quality is reported, action is taken, and air quality improves,” said  Frank Hammes, Global CEO, IQAir in an official press statement.

    Local and regional efforts are required to manage air pollution in Pakistan, as well as strengthening and capacity building of the regulatory bodies for monitoring emissions.

    Source link

    Have you ever noticed the hazy smog that hangs over cities or the lingering smell of exhaust fumes from traffic? These are just a few noticeable signs of air pollution, a threat that can have a significant effect on our health and well-being.

    What is air pollution?

    Air pollution is caused when harmful substances are released into the atmosphere. These pollutants can come from both natural and human-made sources. Natural sources include dust, pollen, volcanoes, and wildfires. Human-generated sources include emissions from vehicles, power plants, factories, agriculture, and burning of wood and other fuels. 

    Where is the air polluted?

    Air pollution can occur anywhere, but certain conditions can make it worse. According to the Environmental Protection Agency (EPA), air pollution levels tend to be highest in urban and industrial areas and near busy roads. 

    While we typically think of air pollution as only an outdoor problem, it’s important to know that indoor air can also be polluted. Indoor air pollution comes from sources such as cooking stoves, fireplaces, and air conditioners. Even household pets can contribute to indoor air pollution when they shed allergens from their skin or hair.  

    How can polluted air make you sick?

    Breathing in polluted air can contribute to health issues, especially in the respiratory system. 

    In the short term, breathing polluted air can irritate your eyes, nose, and throat. It can cause you to cough, wheeze, or have trouble breathing. It can also make certain health conditions and their symptoms worse. 

    Over time, exposure to air pollution can even create more severe health problems. These include:

    • Respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD)
    • Heart disease and stroke
    • Cancer, particularly lung cancer

    Researchers studying air pollution continue to learn more about air pollution’s many health effects every day. 

    Who is at risk?

    While air pollution affects people of all ages and backgrounds, certain groups are more vulnerable to its harmful effects. They include: 

    • Children. Their developing lungs are more susceptible to damage from pollutants.
    • Older adults. They are more likely to have preexisting health conditions that can get worse due to air pollution.
    • People with asthma and other respiratory problems. Their airways are more sensitive to pollutants, which can trigger symptoms.
    • People living in more polluted areas. Those living in urban and industrial areas with high pollution levels are more likely to experience harmful health effects. 

    How can you protect yourself from air pollution?

    Even though it’s impossible to avoid polluted air completely, you can take steps to protect yourself from its harmful effects.

    • Stay informed. Check your local air quality index (AQI) regularly. EPA’s AQI tool at AirNow.gov provides current air quality conditions in your area. 
    • Reduce outdoor exposure. Limit outdoor activities when air pollution levels are high. Try to stay indoors as much as possible. If you need to go outside, plan to do so in the early morning or late evening when levels are typically lower.
    • Avoid polluted areas. Stay away from busy roads and highways, especially during rush hour.
    • Improve indoor air quality. Ventilate your home, use air purifiers, and choose low-emission cleaning products. Don’t burn candles, incense, or wood indoors, and open your windows when you’re cooking. 
    • Don’t smoke. Smoking contributes to air pollution and increases your overall risk of health problems.

    Source link

    It’s been four years since a near-perfect storm hit the U.S. West. COVID-19 was officially declared a pandemic by the World Health Organization in March 2020, just months before the worst wildfire season in recorded history.

    The interactions between wildfire and COVID-19 were large and sweeping, research in the years since has shown. The 2020 season left lasting impacts on the wildland firefighting force, both systemically and personally.

    Wildland firefighters are at high risk for both COVID-19 infection and, when infected, experiencing severe illness from the virus, research published in the National Library of Medicine and Science academic journals found. Researchers in one study examined potential health and workforce capacity impacts by modeling the movement of suppression resources across the country over a season and the corresponding potential for disease spread and cascading outbreaks across wildfire incidents.

    inbound and outbound firefighters on a Montana fireinbound and outbound firefighters on a Montana fire

    The increased risk stems primarily from firefighters’ exposure to wildfire smoke, limited access to hygiene supplies, and constantly being physically near other wildland firefighters and the public.

    IHC superintendents were surveyed by USFS researchers a year after the fires burned. At the beginning of the pandemic, the agency launched a wide range of new practices for hotshot crews to limit the spread of COVID-19 while also, it was hoped, improving operational efficiency. New practices included changes in pre-fire preparation, using virtual paperwork and briefings, and reformatting traditional fire camps to a more widespread layout. The USFS also created a COVID-19 Incident Risk Assessment Tool for fire managers; it measured numerous factors including camp size, mitigation techniques, and number of positive cases to estimate how at-risk each crew was.

    The researchers wanted to know if superintendents were interested in maintaining any of those practices in daily hotshot crew use in the years after 2020, regardless of COVID-19. The survey found that the majority of practices contributed positively to operational efficiency in addition to crewmember safety and well-being. Most respondents preferred the ease of virtual vs. in-person paperwork and briefings, they liked having crews spike on or near the line with the full-scale ICP camp away from the fire, and they felt better physically and mentally as a result of these changes.

    Wildland firefighter well-being — and proper pay — are still a major focus for the USFS post-2020 as retention becomes an increasingly worrying issue. Research conducted this year on retention found that highly skilled wildland firefighters with a high number of assigned days, payment of additional annual earnings, and gained experience throughout the firefighter’s career all had positive effects on retention. Local wages of alternative occupations in a firefighter’s local area had no significant effect on retention.

    The future of wildland firefighter physical health may also see improvements thanks to technological developments stemming from COVID-19. Respiratory illnesses like coronavirus, and other long-term health risks firefighters face such as lung cancer and cardiovascular disease, may be seen in firefighters less and less as mobile respirators proceed further in development.

    California fitted wildland firefighters with a mobile respirator prototype last October while they dug firelines or cut down trees with chainsaws. The results were mixed.

    “Plenty broke. Hoses popped out of sockets. Straps snapped. Masks slid down sweating faces. Filters became dislodged,” Julie Johnson wrote for the San Francisco Chronicle.

    During this event, firefighters from Cal Fire, L.A. County and the USFS took turns trying out several types of mask. They hiked down a slope and then back up, then pulled off their masks, sweating and breathing hard in triple-digit temps. Each round took only about ten minutes.

    Firefighters shared their impressions with observers: Felt like a muzzle. Was too bulky. Too tight. It slipped off my face once I began to sweat.

    Hearing one of her colleagues say “it’s better than nothing,” Cal Fire’s Sol Espinoza spoke up. “I’d rather take nothing,” she said.

    The test is one of many completed or planned throughout the country as the fire agencies look to lower firefighter mortality from diseases increasingly found to be worsened through wildfire smoke inhalation. Experts have hedged their bets on technology frequently used to keep COVID-19 patients hospitalized with severe cases alive. Adaptations in the technology are still under development as researchers figure out which version might be best suited to meet the dynamic needs of firefighters in the field.

    Espinoza, a firefighter with Cal Fire in San Bernardino. Espinoza said she could never imagine wearing a constrictive device that makes it harder to breathe.

    Typos, let us know HERE, and specify which article. Please read the commenting rules before you post a comment.



    Source link

    Introduction

    Asthma in the pediatric population is present in about one in every 10 children and adolescents around the world, presenting heterogeneous characteristics composed of different clinical phenotypes and endotypes.1,2 The underlying cellular and molecular mechanisms (endotypes) of asthma have been represented by Th2 and non-Th2 inflammatory patterns. The Th2 inflammatory pattern, which responds well to the use of inhaled corticosteroids (ICS), accounts for approximately 50 to 60% of asthma in the pediatric population. In this spectrum of inflammation, allergic eosinophilic asthma is the most prevalent in children and adolescents, in which environmental allergens become real villains.3

    On the other hand, the non-Th2 inflammatory pattern represents a significant and growing number of patients who do not respond well to the use of IC and are classified as having neutrophilic or paucigranulocytic asthma (Figure 1). In non-Th2 inflammation, the allergic components are not present in the patient and the immune responses are triggered mainly by the stimulus of pollutants and inhaled irritants, with an important participation of type 1 helper T cells (Th1) and 17 (Th17), in addition to pro-inflammatory interleukins such as IL-17, IL-25, IL-33 and thymic stromal lymphopoietin (TSLP).4

    Figure 1 Participation of pollutants and inhaled irritants in inflammation of the respiratory epithelium in different asthma endotypes.

    In the hypothesis of the epithelial barrier, the inflamed bronchial mucosa becomes hyper-reactive to various stimuli, whether allergic or not, which can trigger episodes of asthma exacerbations. Among the environmental risk factors, allergens stand out, represented mainly by house dust mites, dog and cat hair, cockroaches, fungi, pollens, among other well-known triggers of asthma exacerbations.5

    Growing interest has been focused on pollutants and inhaled irritants present in the home, inside or adjacent to the internal space of the residence, which can harm the respiratory tract and trigger clinical worsening of asthma. Tobacco smoke, use of charcoal stoves, firewood, gas stoves, particulate matter, volatile substances from chemicals used in household cleaning or swimming pool cleaning, use of pesticides, among many, often forgotten, but which may be present in the home environment and need to be detailed in the clinical history of every patient with or without allergic asthma.6,7

    The environment to which the individual is exposed (exposome) continuously influences the clinical control of asthma. The exposome concept considers an individual’s environmental, behavioral, and lifestyle exposures over a lifetime and how these exposures relate to health. In the context of asthma, there are well-known associations, associations that are not fully established, and exposures that demonstrate more distinct effects based on age, chronicity of exposure, and genetic predispositions.8

    Health professionals become the first link in the investigation of environmental factors and how they impact the pathogenesis, symptoms, evolution and morbidity of asthma. When it comes to asthma in the pediatric population, a complex disease with an important gene-environment interaction, the caregiver’s role in the home environment becomes essential.9 Under Antonovsky ‘s salutogenic view, the caregiver represents the most effective agent in promoting home environmental control to avoid both allergic sensitization and asthma exacerbation crises.10

    The central concept of Antonovsky ‘s Salutogenic theory is called sense of coherence (SOC), an individual construct that influences habits that directly interfere with health and adaptive behaviors that can minimize the severity of diseases. The SOC has three main components: the ability to understand an event (comprehensibility), the perception of the potential to manipulate or solve it (manageability) and the meaning given to this event (significance). It consists of a global orientation towards seeing life as structured, manageable and with an emotional meaning.11

    The Salutogenic theory (saluto = health; genesis = origin) proposed in 1979, by Antonovsky – Israeli American sociologist and professor, states that health-promoting factors have a direct impact on the patient’s quality of life. Its assumptions consider health as a result of the adaptive capacity of human beings in the face of life’s adversities.12 When it comes to home environmental control, the caregiver becomes a key player in preventing and controlling exposure to inhaled products and substances that can alter the clinical control of asthma.

    In this context, it is important for health professionals to identify and guide caregivers about the likelihood of certain pollutants and irritants in the home inhalation triggering clinical worsening of asthma. Therefore, this integrative review proposes to present the most common and frequent pollutants or inhalation irritants that can be found in the home environment, highlighting their possible repercussions in the worsening of health through aggression to the respiratory epithelium and consequent impairment of lung function in pediatric patients with asthma, and in this context, highlight the caregiver’s role - through the salutogenic perspective - as a modifying agent for adequate environmental control.

    Materials and Methods

    Selection Criteria

    The research was carried out in the databases MEDLINE/PubMed, Latin American and Caribbean Literature in Health Sciences (Lilacs), Web of Science and Scopus, with the objective of describing the pollutants and inhalant irritants most found in the home environment, their possible repercussions on the respiratory epithelium and lung function that can worsen health and worsen the clinical control of asthma in the pediatric population. The sense of coherence of the salutogenic theory has been investigated in studies directed at asthma and other diseases.

    Search Strategy

    The following descriptors were used: air pollution AND asthma OR/AND lung function; irritants AND asthma; tobacco AND asthma AND pulmonary function; particulate matter AND asthma; disinfectants AND asthma OR/AND lung function; hydrocarbons, fluorinated AND asthma; odorants AND asthma; chloramines AND/OR pool AND asthma; pesticide AND asthma AND lung function; Antonovsky ‘s sense of coherence. The inclusion criteria used for the research were: observational or experimental articles related to the repercussions of pollutants and inhaled irritants on the respiratory tract in humans, in addition to review articles that were published in the last 10 years, in English and Spanish, searched up to September 2023; and a textbook on the sense of coherence of Antonovsky ‘s salutogenic theory (Figure 2).

    Figure 2 Article search strategy flowchart.

    This article is focused only on pollutants and irritants of an inhalation nature, which can be frequently identified in any household and which have a potential deleterious effect on the respiratory tract. It highlights, therefore, the main products found, properties of action and possible repercussions in the worsening of health, especially in asthma, but it does not intend to be an exhaustive review on the subject.

    Publications such as comments, editorials, letters, studies with results from other affected organs other than the respiratory tract, studies that projected exposure effects on the child during the mother’s prenatal period, animal studies, case reports and duplicate articles were excluded. After sorting by reading the titles and abstracts evaluated by the reviewer (G.V.A.G.L.), the full reading began, with more articles being included through manual search, through the references of the initially pre-selected studies on the subject. Although animal studies were not included, studies of some substances in the respiratory tract of animals may have been cited to better elucidate the pathogenic mechanisms of inflammation in asthma.

    Which Pollutants and Irritants in the House May Aggravate the Health of Patients with Asthma?

    Early identification and removal of polluting particles and inhaled irritants, especially in the home environment, are effective ways to maintain health and prevent asthma exacerbations. The lungs are structures widely exposed to ambient air, with approximately 100 square meters of surface area in contact with the outside world, compared only to the skin in terms of the intensity of environmental exposure. With each respiratory movement, various particles, gases and microorganisms transit between the ambient air and the alveoli, which may cause sensitization or damage to the respiratory epithelium.13

    Allergic tests can identify sensitization to inhaled antigens and their correlation with the clinic define an allergic pattern in the individual. Negative tests, therefore, are useful to exclude an allergic basis for asthma and it is in this context that the environmental recall becomes even more essential to identify substances and inhaled particles, present in the home, that can trigger symptoms and exacerbation crises of asthma. Asthma in the pediatric age group, a period totally susceptible to the care of a caregiver responsible for environmental control.14,15

    Substances and inhaled products that can be found in the home environment should be identified by health professionals who care for patients with asthma in the pediatric age group, to better guide caregivers on what should be avoided to protect the patient’s health. Below, the seven main and most common products considered irritants and pollutants inhaled at home, which can worsen the patient’s respiratory health, will be listed and commented on (Table 1).16–26

    Table 1 Substances Identified in the Home Environment That Can Affect the Airways

    Secondhand Smoke Exposure in the Pediatric Population

    Secondary exposure to environmental tobacco, cigar, or e-cigarette vapors has been associated with increased chances of exacerbations and lack of clinical control of asthma. Effects of pre- or postnatal tobacco smoke constitute one of the most important risk factors for childhood asthma, leading to alterations in lung development, even in utero, and in immunological and epigenetic responses that favor asthma.27,28

    Tobacco smoke, now so well known, is a mixture of compounds including carbon and nitrogen oxides, particulate matter, nitrosamines, polycyclic aromatic hydrocarbons, carbonyls, and numerous other chemicals, many of which are known toxicants that can induce inflammation and responses altered immune. Among these compounds, nicotine and its metabolites are the most responsible for chemical dependence and deleterious effects on the lungs, such as intense inflammatory reaction, allergic sensitization and changes in lung function.29

    Negative health outcomes are not limited to indoor smoking, but also the continued elimination of tobacco compounds from people who smoked outside the home. In addition, residues from tobacco smoke, known as third-hand smoke, can persist for weeks to months in the home, adhering to surfaces and house dust after the smoke has evaporated. The residue is composed of chemicals that can react with other atmospheric pollutants, forming volatile toxic particles.30

    Nicotine metabolites, such as cotinine, have been used as an objective measure of passive exposure in epidemiological studies. Self-reported measurements of exposure to secondhand smoke did not show good specificity when compared to measurements of plasma cotinine. In fact, approximately 41% of children whose parents reported in the clinical history that they were not active smokers in the household had detectable levels of plasma cotinine, with mean plasma cotinine levels increasing as the number of household smokers increased.16

    On the other hand, the use of electronic cigarettes has been replacing the use of conventional cigarettes and has been increasingly used by adolescents. Recent findings suggest that e-cigarettes, also known as e-cigs, electronic nicotine delivery devices, e-vaporizers or vapers, can cause respiratory damage in a similar way to traditional cigarettes and still pose other risks to users and passive inhalants.31

    Vapers are devices that have a battery, an atomizer and a tank or cartridge to contain the e-liquid composed of propylene glycol and vegetable glycerin, in addition to several other compounds of common cigarettes, which when they decompose form carbonyl compounds with known inhalation toxicity and irritating properties to the respiratory epithelium. Other harmful compounds are liquid flavorings, such as diacetyl (2,3-butanedione), which can cause irreversible lung disease.32

    Flavoring agents with potential respiratory hazards due to possible volatility and respiratory irritant properties are: acetoin, camphor, and cyclohexanone (minty flavor), benzaldehyde (cherry or almond flavor), cinnamaldehyde (cinnamon flavor), cresol (leather or medicinal flavor), butyraldehyde (chocolate flavor) and isoamyl acetate (banana flavor).33

    Although smoking cessation is the most appropriate strategy, this has not been shown to be a intervention, as it depends on the cooperation of the smoker’s family members. Smoking outside the home may not be an effective mitigation strategy due to the residual risk of smoking.34 It is important to advise caregivers to stop smoking and keep the home environment free of tobacco smoke, cigars or electronic vaporizers, as the health risks are serious and passive smoking has been associated with a worse clinical outcome of asthma in childhood and adolescence.

    Particulate Matter (PM) Indoors

    Particulate matter (PM) can be formed by solid or liquid particles that remain in air suspension invisibly, different from large particles, which can be visible with appropriate lighting, such as fog or dust. These particles can be organic chemical compounds, acids such as sulfates and nitrates, metals and even dust. PMs are identified by their aerodynamic size or diameter: PM0.1 is < 0.1µm in diameter, PM2.5 is < 2.5µm and PM10 is < 10µm in diameter and are commonly emitted from combustion sources.35

    The fine particles (PM2.5) manage to reach the pulmonary alveoli, where they will be captured by local cells and transported by the bloodstream, whereas the finer particles (PM0.1) pass through the alveolar-capillary membrane and confer greater systemic toxicity. In many parts of the world, smoking, incense burning, candles and mosquito coils are the main sources of PM2.5 indoors, where poor ventilation in homes can lead to extremely high levels of indoor pollution and deterioration of the environment lung function.36

    The burning of incense for religious ceremonies or to perfume the air at home, in addition to the burning of repellents to eliminate mosquitoes, have generated toxic pollutants that have been associated with alveolar oxidative damage, respiratory diseases and even lung cancer.20

    Particles resulting from the combustion of fossils, especially from the combustion of biomass (coal) used in home cooking, contain many heavy metals on their surfaces, such as arsenic, lead, cadmium or compounds such as sulfuric acid or cyclic aromatic hydrocarbons, which can be captured during the combustion process and transported on the surface of finer particles (PM2.5) to the pulmonary alveoli. Although the world still depends on biomass fuel for cooking and heating, it is known that public policies for environmental control are still limited. The use of firewood or coal for residential cooking and heating, in poor and cold geographic regions, has become frequent, especially in low-income countries.7

    Natural gas is a popular fuel choice for home cooking. Among all gas appliances, stoves, cooktops and ovens in homes have their particularities, because combustion by-products are emitted directly into the domestic air, such as methane gas, formaldehyde (CH2O), carbon oxide (CO) and nitrogen oxides (nitric oxide - NO and nitrogen dioxide - NO2) and cause oxidative stress with inflammation, changes in lung function and a significant increase in Th2 profile pro-inflammatory cytokines.26

    Repercussions on the respiratory tract can be observed even in early but intense phases of exposure to these materials suspended in the air. PM can also lead to chronic local inflammation and even pulmonary fibrosis in prolonged exposures. When there is overload of the macrophage function and the cells of the respiratory epithelium are exposed, oxidative stress is triggered and a cascade of inflammatory events, with production of cytokines IL-25, IL-33, TSLP, become evident.36

    Special consideration is also being given to microplastics (PMs), which have a diameter of less than 0.5 cm and can be found in the air, indoors. The main sources of PMs for indoor air can be identified in textile products (clothes, curtains, mattresses), toys, rubber materials, kitchen utensils (plates, cups, bowls, bottles), electrical cables, electronics, indoor paint and cleaning agents, with a higher concentration in bedrooms.37

    Inhalation is the main route of human exposure to microplastics and their accumulation in the human airways can cause inflammatory and immune responses in the lung interstitium due to the cytotoxic effect of the particles. Oxidative stress with repercussions on lung function are the main results of respiratory epithelial damage.38

    Guidance for caregivers should emphasize the importance of having a ventilated home environment, with windows, preferably in urban areas free of burning garbage or biomass close to housing, clarify the risks that cooking indoors can bring to children’s lungs asthmatic and responsible. Alternatives such as having charcoal stoves outside the home, in the open air, or in ventilated residential annexes, can reduce exposure to particulate matter, especially in low-income populations.39

    Substances in Household Cleaning Products

    There are a variety of cleaning products and quantitative assessments of their presence in the air are challenging because these products are complex mixtures of chemicals that require different sampling methods and analytical measurement.40

    Chemicals that require the most attention in relation to respiratory effects in asthma are corrosive ones, such as strong acids and bases (including ammonia and hypochlorite) and quaternary ammonium compounds. Solvents, including glycols and glycol ethers, as well as propellants, which are generally weak lower airway irritants, can potentiate the effects on the respiratory epithelium, especially if they are mixed in the same cleaning product.41

    In Table 2, the chemical substances are presented according to the main molecular group, properties of action and risks of exacerbation or induction of asthma in people who may be exposed during household cleaning. We identified 24 substances that are more present in general cleaning products in spray or volatile form and that exert an irritating mechanism on the respiratory epithelium; three substances have the potential to sensitize asthma (benzalkonium chloride, ethylenediamine acid tetraacetic – EDTA and monoethanolamine); and six substances (salicylic acid, sodium benzoate, propylene glycol, glycerol, propylidinetrimethanol and bronopol) have little evidence as possible sensitizers in asthma.40,42

    Table 2 Characteristics of Chemical Substances Found in Residential Cleaning Products

    More than 95% of volatile household cleaners contain chemicals that can irritate the respiratory epithelium. For example, sanitizers, considered disinfectants and degreasers, may contain citric acid, nitrilotriacetic acid, ethylenediamine acid tetraacetic acid (EDTA), benzalkonium chloride, monoethanolamine, diethylene glycolamine, alkyldimethyl amino oxide, methylisothiazolinone, benzisothiazolinone, chlormethylisothiazolinone, sodium benzoate, propylene glycol, glycerol, propylidinetrimethanol, lactic acid, malate disodium and salicylic acid. Liquid waxes for illustrating furniture and floors may contain bronopol and morpholine. Cleaning products that give off fragrance may contain benzyl alcohol. Descalers may contain sulfamic acid, and disinfectants and bleaches may contain sodium hypochlorite, sodium p- cumenesulfonate, and carmoisine.40

    Guidance on avoiding the use of cleaning products or spray preparations containing mainly benzalkonium chloride and EDTA is important to prevent the induction or worsening of asthma, especially for those patients who are under the care of a guardian and are vulnerable to the dynamics cleaning in the residential environment. If the use of these spray preparations is not prohibitive, guidance can be given on keeping children with asthma away from home during the cleaning period at home and on the use of a mask by the caregiver. The recommendation for caregivers is that these products can be replaced or that the limitations of using these substances, especially in sprays, in closed environments be informed.43

    Fluorinated Hydrocarbons

    Chlorofluorocarbons (CFCs) and hydrochlorofluorocarbons (HCFCs), known as freons, were used as refrigerants until the early 2000s. Due to their ozone-depleting properties, freons have increasingly been replaced by chlorine-free refrigerants such as fluorinated hydrocarbons.44

    Fluorinated hydrocarbons, which can thermally degrade to toxic hydrofluoric acid, are widely used as cooling agents in air conditioning systems, refrigerators, and as propellants in some medical aerosols. When fluorinated hydrocarbons are used in the presence of combustion, thermal degradation can lead to the formation of hydrofluoric acid, which is a known causative agent of irritant-induced asthma. Therefore, combustion sources, such as fireplaces, can be a risk for those using air conditioning in closed rooms and in confined residential environments.21

    Hydrofluoric acid is associated with chemical pneumonitis, especially after exposure indoors, resulting from the combustion of fluorinated hydrocarbons, causing respiratory symptoms and changes in lung function after months of exposure. Guidance for caregivers, as providers of home security and well-being, should emphasize the risks of using fireplaces and heaters indoors, especially in bedrooms. In addition to the risks of inhaling particulate matter, the products of combustion and thermal degradation lead to the formation of substances that irritate the respiratory epithelium with a potential risk of exacerbating asthma.45

    Fragrances and the Respiratory Tract

    Although most of the substances used to generate the fragrance of perfumes are benign, a minority have the potential to cause adverse health effects, notably allergic contact dermatitis resulting from skin sensitization to compounds such as isoeugenol or eugenol. As a result, industry guidelines, as well as comprehensive trade bodies, of which perhaps the most important is International fragrance Association (IFRA), have banned certain materials and strictly limited the use of others in their products.46

    In a recent review, Basketter et al concluded that mechanisms of allergic sensitization with the use of fragrances seem highly unlikely to occur in the respiratory epithelium. Although some sensory/psychosomatic effects are possible, adverse effects to the respiratory tract resulting from fragrance inhalation are uncommon and minimal, with low irritating characteristics, which highlight the need for methodologically rigorous studies supported by the Bradford Hill causality criteria, based on the biological plausibility of the reaction of the indicated substance. Preferably, guidelines for caregivers are related to the excess of these products in closed environments, which should be avoided, especially those containing strong fragrances.47

    Volatile Pool Compounds

    The need for entertainment space at home has become urgent in recent years, both due to the current behavior of society and the safety and comfort that are generated. The presence of a swimming pool in a residential environment or even its use in leisure environments are reasons for constant concern by caregivers of children who suffer from allergic respiratory processes.48

    Regular physical activity in people with controlled asthma is recommended, as it improves general health and physical resistance, as well as improves parameters of cardiopulmonary capacity, although it is known that increased physical activity can cause exertional bronchial spasm and exacerbation of bronchial asthma in some partially controlled patients.49

    During swimming, bronchial ventilation can increase by 20 to 30 times, which can lead to a change in breathing pattern from nasal to mixed (nasal and pulmonary). Hyperventilation and cold air can induce bronchial spasm through water loss and increased osmolarity in bronchial tissues which, in turn, trigger the release of cellular inflammatory mediators, histamine, prostaglandin, and leukotrienes. In addition, increased bronchial ventilation promotes the penetration of air pollutants, allergens and other nearby irritants. Despite this, swimming is associated with less intensity of post-exercise bronchial spasm compared to running or other sports with the same intensity.50

    The most used method of disinfecting swimming pools is the addition of chlorine, however, the reactivity of chlorine to compounds present in the body of a swimmer, such as the epidermis, urine, sweat, remains of impurities, results in the formation of a wide range of disinfection by-products (DBPs) such as monochloramines, dichloramines, trichloramines, trihalogenomethanes, haloacetic acid, some of which are known to be associated with adverse effects on the respiratory epithelium. Among the DBPs formed in swimming pools, among which more than 10 volatile compounds can be found, is trichloramine (NCl3). NCl3 is formed as a by-product of disinfection in chlorinated pools and can be found in liquid and gaseous phases.51

    In a Cochrane systematic review, the authors collected data from randomized clinical trials (RCTs) and quasi- RCTs of children and adolescents comparing swimming with other physical activity and concluded that there was no evidence that swimming caused adverse effects in asthma control in young people under 18 years of age with stable asthma of any severity. In a more recent meta-analysis, using RCTs, quasi-experimental studies and intervention studies with disinfection products for swimming pools, the authors concluded that swimming did not result in adverse effects, on the contrary, it resulted in a reduction in bronchial hyperreactivity and bronchospasm exercise-induced.52

    Due to the growing publications on the risks of DBPs in the respiratory tract of home recreational swimmers, there is a need for comparative studies between pool chlorine and other disinfectants considered alternatives, such as ozone, ultraviolet radiation, bromine and salt, in addition to silver and copper ions. The most suitable microbiological and chemical method is the ozonation of water, however, due to the high cost, this method is little used. In the case of using pools with chlorinated water, the guidance to caregivers is that patients with controlled asthma should practice all sports, including swimming. It is important that the pool has air circulation and is installed in an open environment to facilitate the dispersion of compounds suspended in the air.53

    Exposure of Pesticides at Home

    Pesticides are identified as chemical products that can be presented in different formulations and concentrations to be used in different environments: family farming, domestic use, animal sanitary bath and vector control. Situations of exposure vulnerability to these products can be identified regarding: improper disposal of containers, storage in internal rooms of the house, inadequate agricultural practices and lack of awareness of the potential dangers of these products, promoting a greater risk of harmful effects on the environment health during childhood. The concern with children’s exposure to pesticides is related to their toxic properties and the special vulnerability to exposure, which can occur from the prenatal period to older ages.54

    There is a wide variety of chemicals (more than 9000 globally), presented in different formulations and concentrations. The classification of pesticides can correspond to their assignment, for example, insecticides, herbicides, fungicides, disinfectants, repellents and rodenticides. Another practical approach is to classify according to recommendations for use, for example, products for gardening, vector control, veterinary (animal baths) and agricultural.26

    In general, children constitute a special exposure group, which can occur through multiple routes (transplacental, inhalation, skin and ingestion) simultaneously or sequentially during life. Inhalation of toxic substances occurs through breathable particles or aerosols that are spread by direct application of the product at home or through residual volatile vapors from pesticides applied adjacent to the home.55

    Rural households are in an even more dangerous scenario, because children can inhale pesticides that are sprayed on freshly treated crops in the home area or have these products stored indoors. Some pesticides are well known and are part of the products that can be inhaled, among them acaricides (carbamates, nitrophenol derivatives, organochlorine compounds, organophosphate compounds), fungicides (dinitrophenols, thiocarbamates and dithiocarbamates, sulfur), herbicides (anilides, sulfonylureas, paraquat), insecticides (carbofuran, malathion, cypermethrin), rodenticides (warfarin) and repellents (diethyltoluamide). All these pesticides have a common characteristic, when applied they become volatile and can trigger an intense irritative process in the respiratory epithelium, some even pulmonary fibrosis, such as paraquat.54,56

    Health professionals who assist patients, who come mainly from rural areas, must be careful to take a good clinical history and identify the pesticides that can cause clinical worsening of asthma. Once factors that facilitate the child’s exposure to these products have been identified, their caregivers need to be instructed to avoid handling and using them at home. Alternatives to the use of natural products should be encouraged to replace these pesticides.56

    Reflections on the Role of the Caregiver in Integration with Asthma Patient Health Maintenance

    One of the main effective actions in asthma management is to avoid exposure to environmental allergens, pollutants and inhaled irritants. In the pediatric population, asthma reflects some singularities, since children and adolescents are passive agents and the greatest demand for maintaining adequate environmental control falls on caregivers.1

    Although there is no description in the literature of publications on the caregiver’s sense of coherence and environmental control in asthma, this article presents a new look at an old problem, now guided by the salutogenic perspective: promoting a healthy home environment, with reduction and prevention of exposure to pollutants and inhaled irritants will have positive repercussions on the clinical control of asthma.

    Previous studies have shown that a high sense of coherence is related to better health outcomes, and this has been observed in the care of diabetic patients, with neurological diseases, autoimmune diseases, neoplastic diseases, in oral health care and even during the covid-19 pandemic.57,58 SOC, a construct of Antonovsky ‘s salutogenic theory, is a personal orientation for identifying, coping and solving problems, which has become a fundamental concept in public health, particularly for health promotion.59

    Antonovsky ‘s inspiration for researching this phenomenon came when he studied climacteric women who had lived in concentration camps during World War II, finding that some of them maintained good physical and mental health. For the creator of the salutogenic theory, SOC has a direct effect on people’s health status, acting in such a way as to stimulate behavior patterns that promote health benefits. The SOC would be related to the ability to perceive one’s own body and the environment that surrounds it, determining whether the situation to which the individual is exposed is dangerous, safe or pleasant.10

    The formation of the SOC is a continuum, being developed in childhood, built through the interactions of the social and family environment, and formed around 30 years of life, and can be extended to more advanced ages. It is believed that the SOC is an individual resource that can influence health behaviors, in the search for better clinical control, especially of chronic diseases.11

    From the perspective of clinical asthma control, a high SOC may promote changes in the household exposure. Not only will aeroallergens be identified and avoided, but pollutants and inhaled irritants will be removed from the environment, especially from children and adolescents with asthma. Caregivers of patients with asthma will be the modifiers of the home environment, making the living space adequate to prevent asthma exacerbations. Figure 3 illustrates, in addition to environmental allergens, the main products and irritants that can affect the health of asthmatics and the role of protection and promotion of asthma control from the salutogenic perspective of a caregiver.12

    Figure 3 Home scenario with possible allergens, pollutants and harmful inhalation irritants for the child with asthma, highlighting the role of the caregiver, under the salutogenic perspective.

    Conclusion

    As part of the development of strategies regarding environmental control measures, a history of the home environment should be obtained to assess the main exposures to which the patient with asthma is subject. Environmental control approaches should be evidence-based and aimed at reducing these exposures as an important part of asthma management.1

    Personalized and multifaceted environmental interventions, particularly in the home environment, are endorsed by international guidelines and may be similar in terms of effectiveness to controller medications. Environmental control measures for total removal of the source (eradication of the allergen or inhaled irritant), mitigation strategies (reduction of the amount of these substances in the air) and source control (control in the production of inhaled pollutants) have been described and advocated by the main guidelines of asthma, such as the National Asthma Education and Prevention Program (NAEPP) and the Global Initiative for Asthma (GINA).60

    One of the limitations of current knowledge is that many other substances in the future may be identified as related to exacerbations and clinical worsening of asthma and have not yet been analyzed in studies with adequate methodology, as the topic is broadly addressed.

    Environmental control recommendations, therefore, include prior knowledge of the most common pollutants and inhaled irritants that can be found at home; guidance and education for caregivers of children and adolescents with asthma on how to reduce exposure; adaptation of environmental control measures according to the patient’s socioeconomic conditions and the participation of public health policies in facing the commercialization of products that are known to be harmful to health, in particular to the respiratory epithelium.

    Studies that investigate the relationship between the caregiver’s SOC and clinical control of asthma, focusing on home environmental control, are important and necessary, so that intervention measures can be effectively adopted for the adequate management of asthma in the pediatric population.

    Abbreviations

    ICSs, inhaled corticosteroids; IL, interleukin; Th, helper T; IgE, immunoglobulin E; TSLP, thymic stromal lymphopoietin; SOC, sense of coherence; PM, particulate matter; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DBPs, disinfection byproducts; NCl3, trichloramines; EDTA, ethylenediamine tetraacetic acid; CFCs, chlorofluorocarbons; HCFC, hydrochlorofluorocarbon; IFRA, international Fragrance Association; RCTs, randomized clinical trials; NAEPP, national asthma education and prevention program; GINA, global initiative for asthma.

    Acknowledgments

    The authors would like to acknowledge the Postgraduate Program in Child and Adolescent Health linked to the Coordination for the Improvement of Higher Education Personnel (CAPES) and the National Council for Scientific and Technological Development (CNPq).

    Author Contributions

    All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

    Funding

    This study did not receive any specific funding.

    Disclosure

    The authors have no conflicts of interest to declare for this work.

    References

    1. Martin J, Townshend J, Brodlie M. Diagnosis and management of asthma in children. BMJ Paediatr Open. 2022;6(1):e001277. doi:10.1136/bmjpo-2021-001277

    2. Hurst JH, Zhao C, Hostetler HP, Ghiasi Gorveh M, Lang JE, Goldstein BA. Environmental and clinical data utility in pediatric asthma exacerbation risk prediction models. BMC Med Inform Decis Mak. 2022;22(1):108. doi:10.1186/s12911-022-01847-0

    3. Altman MC, Calatroni A, Ramratnam S, et al. Endotype of allergic asthma with airway obstruction in urban children. J Allergy Clin Immunol. 2021;148(5):1198–1209. doi:10.1016/j.jaci.2021.02.040

    4. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783–800. doi:10.1016/S0140-6736(17)33311-1

    5. Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Epithelial barrier hypothesis: effect of the external exposome on the microbiome and epithelial barriers in allergic disease. Allergy. 2022;77(5):1418–1449. doi:10.1111/all.15240

    6. Cockcroft D. Environmental causes of asthma. Semin Respir Crit Care Med. 2018;39(01):012–018. doi:10.1055/s-0037-1606219

    7. Rosário Filho NA, Urrutia-Pereira M, D’Amato G, et al. Air pollution and indoor settings. World Allergy Organ J. 2021;14(1):100499. doi:10.1016/j.waojou.2020.100499

    8. Subramanian A, Khatri SB. The exposome and asthma. Clin Chest Med. 2019;40(1):107–123. doi:10.1016/j.ccm.2018.10.017

    9. Busse WW, Kraft M. Current unmet needs and potential solutions to uncontrolled asthma. Eur Respir Rev. 2022;31(163):210176. doi:10.1183/16000617.0176-2021

    10. d’Alessio PA. Salutogenesis and beyond. Dermatol Ther. 2019;32(1):e12783. doi:10.1111/dth.12783

    11. Lindström B, Eriksson M. Contextualizing salutogenesis and antonovsky in public health development. Health Promot Int. 2006;21:238–244. doi:10.1093/heapro/dal016

    12. Bhattacharya S, Pradhan KB, Bashar MA. Salutogenesis: a bona fide guide towards health preservation. J Fam Med Prim Care. 2017;6(2):169–170. doi:10.4103/jfmpc.jfmpc

    13. Leas BF, D’Anci KE, Apter AJ, et al. Effectiveness of indoor allergen reduction in asthma management: a systematic review. J Allergy Clin Immunol. 2018;141(5):1854–1869. doi:10.1016/j.jaci.2018.02.001

    14. Custovic A, de Moira AP, Murray CS, Simpson A. Environmental influences on childhood asthma: allergens. Pediatr Allergy Immunol. 2023;34(2):1–19. doi:10.1111/pai.13915

    15. Raju S, Siddharthan T, McCormack MC. Indoor air pollution and respiratory health. Clin Chest Med. 2020;41(4):825–843. doi:10.1016/j.ccm.2020.08.014

    16. Neophytou AM, Oh SS, White MJ, et al. Secondhand smoke exposure and asthma outcomes among African-American and Latino children with asthma. Thorax. 2018;73(11):1041–1048. doi:10.1136/thoraxjnl-2017-211383

    17. Sugier P, Sarnowski C, Granell R, et al. Genome‐wide interaction study of early‐life smoking exposure on time‐to‐asthma onset in childhood. Clin Exp Allergy. 2019;49(10):1342–1351. doi:10.1111/cea.13476

    18. He Z, Wu H, Zhang S, et al. The association between secondhand smoke and childhood asthma: a systematic review and meta‐analysis. Pediatr Pulmonol. 2020;55(10):2518–2531. doi:10.1002/ppul.24961

    19. Niu X, Jones T, BéruBé K, Chuang HC, Sun J, Ho KF. The oxidative capacity of indoor source combustion derived particulate matter and resulting respiratory toxicity. Sci Total Environ. 2021;767:144391. doi:10.1016/j.scitotenv.2020.144391

    20. Weinmann T, Forster F, von Mutius E, et al. Association between occupational exposure to disinfectants and asthma in young adults working in cleaning or health services. J Occup Environ Med. 2019;61(9):754–759. doi:10.1097/JOM.0000000000001655

    21. Lindström I, Ryhänen A, Jungewelter S, Suojalehto H, Suuronen K. Asthma onset after exposure to fluorinated hydrocarbons in the presence of combustion. Am J Ind Med. 2020;63(11):1054–1058. doi:10.1002/ajim.23181

    22. Saijo Y, Yoshioka E, Sato Y, et al. Relations of mold, stove, and fragrance products on childhood wheezing and asthma: a prospective cohort study from the Japan Environment and Children’s Study. Indoor Air. 2022;32(1):1–9. doi:10.1111/ina.12931

    23. Kanikowska A, Napiórkowska-Baran K, Graczyk M, Kucharski M. Influence of chlorinated water on the development of allergic diseases – an overview. Ann Agric Environ Med. 2018;25(4):651–655. doi:10.26444/aaem/79810

    24. Hwang SH, Park WM. Indoor air concentrations of carbon dioxide (CO2), nitrogen dioxide (NO2), and ozone (O3) in multiple healthcare facilities. Environ Geochem Health. 2020;42(5):1487–1496. doi:10.1007/s10653-019-00441-0

    25. Lebel ED, Finnegan CJ, Ouyang Z, Jackson RB. Methane and NO x emissions from natural gas stoves, cooktops, and ovens in residential homes. Environ Sci Technol. 2022;56(4):2529–2539. doi:10.1021/acs.est.1c04707

    26. Pascale A, Laborde A. Impact of pesticide exposure in childhood. Rev Environ Health. 2020;35(3):221–227. doi:10.1515/reveh-2020-0011

    27. Butz AM, Tsoukleris M, Elizabeth Bollinger M, et al. Association between second hand smoke (SHS) exposure and caregiver stress in children with poorly controlled asthma. J Asthma. 2019;56(9):915–926. doi:10.1080/02770903.2018.1509989

    28. Johansson E, Martin LJ, He H, et al. Second-hand smoke and NFE2L2 genotype interaction increases paediatric asthma risk and severity. Clin Exp Allergy. 2021;51(6):801–810. doi:10.1111/cea.13815

    29. Merianos AL, Jandarov RA, Gordon JS, Lyons MS, Mahabee-Gittens EM. Child tobacco smoke exposure and healthcare resource utilization patterns. Pediatr Res. 2020;88(4):571–579. doi:10.1038/s41390-020-0997-0

    30. Shen M, Li Y, Song B, Zhou C, Gong J, Zeng G. Smoked cigarette butts: unignorable source for environmental microplastic fibers. Sci Total Environ. 2021;791:148384. doi:10.1016/j.scitotenv.2021.148384

    31. Clapp PW, Jaspers I. Electronic cigarettes: their constituents and potential links to asthma. Curr Allergy Asthma Rep. 2017;17(11):79. doi:10.1007/s11882-017-0747-5

    32. Ratajczak A, Feleszko W, Smith DM, Goniewicz M. How close are we to definitively identifying the respiratory health effects of e-cigarettes? Expert Rev Respir Med. 2018;12(7):549–556. doi:10.1080/17476348.2018.1483724

    33. Carson JL, Zhou L, Brighton L, et al. Temporal structure/function variation in cultured differentiated human nasal epithelium associated with acute single exposure to tobacco smoke or E-cigarette vapor. Inhal Toxicol. 2017;29(3):137–144. doi:10.1080/08958378.2017.1318985

    34. Gakkhar A, Mehendale A, Mehendale S. Tobacco cessation intervention for young people. Cureus. 2022;14(10):1–7. doi:10.7759/cureus.30308

    35. Liu C, Chen R, Sera F, et al. Ambient particulate air pollution and daily mortality in 652 cities. N Engl J Med. 2019;381(8):705–715. doi:10.1056/NEJMoa1817364

    36. De Grove KC, Provoost S, Brusselle GG, Joos GF, Maes T. Insights in particulate matter-induced allergic airway inflammation: focus on the epithelium. Clin Exp Allergy. 2018;48(7):773–786. doi:10.1111/cea.13178

    37. Ageel HK, Harrad S, Abdallah MAE. Occurrence, human exposure, and risk of microplastics in the indoor environment. Environ Sci Process Impacts. 2022;24(1):17–31. doi:10.1039/D1EM00301A

    38. Hussain S, Parker S, Edwards K, et al. Effects of indoor particulate matter exposure on daily asthma control. Ann Allergy Asthma Immunol. 2019;123(4):375–380.e3. doi:10.1016/j.anai.2019.07.020

    39. Wu J, Zhong T, Zhu Y, Ge D, Lin X, Li Q. Effects of particulate matter (PM) on childhood asthma exacerbation and control in Xiamen, China. BMC Pediatr. 2019;19(1):194. doi:10.1186/s12887-019-1530-7

    40. Hadrup N, Frederiksen M, Wedebye EB, et al. Asthma‐inducing potential of 28 substances in spray cleaning products—assessed by quantitative structure activity relationship (QSAR) testing and literature review. J Appl Toxicol. 2022;42(1):130–153. doi:10.1002/jat.4215

    41. Vizcaya D, Mirabelli MC, Gimeno D, et al. Cleaning products and short-term respiratory effects among female cleaners with asthma. Occup Environ Med. 2015;72(11):757–763. doi:10.1136/oemed-2013-102046

    42. Clausen PA, Frederiksen M, Sejbæk CS, et al. Chemicals inhaled from spray cleaning and disinfection products and their respiratory effects. A comprehensive review. Int J Hyg Environ Health. 2020;229:113592. doi:10.1016/j.ijheh.2020.113592

    43. Abrams EM. Cleaning products and asthma risk: a potentially important public health concern. Can Med Assoc J. 2020;192(7):E164–E165. doi:10.1503/cmaj.200025

    44. Lawal AT. Polycyclic aromatic hydrocarbons. A review. Fantke P, ed. Cogent Environ Sci. 2017;3(1):1339841. doi:10.1080/23311843.2017.1339841

    45. Lee YJ, Jeong IB. Chemical pneumonitis by prolonged hydrogen fluoride inhalation. Respir Med Case Rep. 2021;32:101338. doi:10.1016/j.rmcr.2020.101338

    46. Santana FPR, da Silva RC, Ponci V, et al. Dehydrodieugenol improved lung inflammation in an asthma model by inhibiting the STAT3/SOCS3 and MAPK pathways. Biochem Pharmacol. 2020;180(May):114175. doi:10.1016/j.bcp.2020.114175

    47. Basketter DA, Huggard J, Kimber I. Fragrance inhalation and adverse health effects: the question of causation. Regul Toxicol Pharmacol. 2019;104(March):151–156. doi:10.1016/j.yrtph.2019.03.011

    48. Andersson M, Backman H, Nordberg G, et al. Early life swimming pool exposure and asthma onset in children – a case-control study. Environ Heal. 2018;17(1):34. doi:10.1186/s12940-018-0383-0

    49. Beggs S, Foong YC, Le HCT, Noor D, Wood-Baker R, Walters JAE. Swimming training for asthma in children and adolescents aged 18 years and under. Cochrane Database Syst Rev. 2013;2013(4). doi:10.1002/14651858.CD009607.pub2

    50. Seys SF, Feyen L, Keirsbilck S, Adams E, Dupont LJ, Nemery B. An outbreak of swimming-pool related respiratory symptoms: an elusive source of trichloramine in a municipal indoor swimming pool. Int J Hyg Environ Health. 2015;218(4):386–391. doi:10.1016/j.ijheh.2015.03.001

    51. Wu T, Földes T, Lee LT, et al. Real-time measurements of gas-phase trichloramine (NCl 3) in an indoor aquatic center. Environ Sci Technol. 2021;55(12):8097–8107. doi:10.1021/acs.est.0c07413

    52. Ramachandran HJ, Jiang Y, Shan CH, Tam WWS, Wang W. A systematic review and meta-analysis on the effectiveness of swimming on lung function and asthma control in children with asthma. Int J Nurs Stud. 2021;120:103953. doi:10.1016/j.ijnurstu.2021.103953

    53. Päivinen M, Keskinen K, Putus T, Kujala UM, Kalliokoski P, Tikkanen HO. Asthma, allergies and respiratory symptoms in different activity groups of swimmers exercising in swimming halls. BMC Sports Sci Med Rehabil. 2021;13(1):119. doi:10.1186/s13102-021-00349-2

    54. Rodrigues MDB, Carvalho DSD, Chong-Silva DC. Association between exposure to pesticides and allergic diseases in children and adolescents: a systematic review with meta-analysis. J Pediatr. 2022;98(6):551–564. doi:10.1016/j.jped.2021.10.007

    55. Islam JY, Hoppin J, Mora AM, et al. Respiratory and allergic outcomes among 5-year-old children exposed to pesticides. Thorax. 2023;78(1):41–49. doi:10.1136/thoraxjnl-2021-218068

    56. Fishwick D, Harding AH, Chen Y, Pearce N, Frost G. Asthma in pesticide users: an update from the Great Britain Prospective Investigation of Pesticide Applicators’ Health (PIPAH) cohort study. Occup Environ Med. 2022;79(6):380–387. doi:10.1136/oemed-2021-107486

    57. Polhuis KCMM, Vaandrager L, Koelen MA, Geleijnse JM, Soedamah-Muthu SS. Effects of a salutogenic healthy eating program in type 2 diabetes (the SALUD Study): protocol for a randomized controlled trial. JMIR Res Protoc. 2023;12:e40490. doi:10.2196/40490

    58. Tóth ÁL, Kívés Z, Szovák E, et al. Sense of coherence and self-rated aggression of adolescents during the first wave of the COVID-19 pandemic, with a focus on the effects of animal assisted activities. Int J Environ Res Public Health. 2022;20(1):769. doi:10.3390/ijerph20010769

    59. Drageset S, Ellingsen S, Haugan G. Salutogenic nursing home care: antonovsky’s salutogenic health theory as a guide to wellbeing. Health Promot Int. 2023;38(2):1–11. doi:10.1093/heapro/daad017

    60. Kader R, Kennedy K, Portnoy JM. Indoor environmental interventions and their effect on asthma outcomes. Curr Allergy Asthma Rep. 2018;18(3):17. doi:10.1007/s11882-018-0774-x

    Source link

    Introduction

    Breathing, a fundamental physiological process that plays a crucial role in overall health and well-being, is often taken for granted.1 According to Nelson et al,2 the core of many breathing exercises is diaphragmatic breathing, which is considered the most fundamental demonstration of core function. These exercises involve retraining the muscles of respiration, improving ventilation, and optimizing gaseous exchange.3

    Diaphragmatic breathing is recognized as a key component of many exercise protocols and practices, such as meditation, ancient eastern religions, martial arts, and yoga exercises. Diaphragmatic breathing involves the active engagement of the diaphragm to facilitate deep and efficient inhalation and exhalation. For instance, yogic breathing exercises, which originate from the yoga tradition, play a significant role in promoting relaxation, optimizing lung function, fostering emotional balance, and facilitating self-regulation.4 Many of these exercise practices and protocols not only offer diaphragmatic breathing but also incorporate other techniques such as nasal breathing, slow exhalation with pauses, smoothness, steadiness, and self-observation.

    Elements of exercise programs in rehabilitation, including the ones mentioned above, have long been recognized for their significant contributions and effectiveness. This type of breathing exercises often encompasses a variety of techniques aimed at improving lung function enhancing oxygenation and strengthening the muscles involved in respiration.5–7 They play a role in helping patients recover from conditions like chronic obstructive pulmonary disease (COPD),8 asthma9 and post-surgical recuperation.10

    Breathing exercises aim to improve pulmonary status, increase endurance, and enhance overall function in daily living activities.3 In particular, traditional breathing exercises such as slow breathing, pursed lip breathing, and incentive spirometry have been proven effective in enhancing respiratory capacity and alleviating symptoms associated with these conditions.11–13 However, the success of these exercises can be influenced by factors such as adherence, motivation levels and the perception of routines.14,15

    Pulmonary rehabilitation (PR) in specific often involves a range of breathing exercises designed to meet the needs of patients. One example is diaphragmatic breathing exercise, which focuses on improving the efficiency of the diaphragm muscle for inhalation.16 This technique encourages deep, slow breaths to maximize lung expansion and enhance ventilation.17 Pursed lip breathing exercise also helps prevent airway collapse by maintaining positive pressure during exhalation reducing breathlessness in conditions like COPD.18 In addition, incentive spirometry devices guide patients through inhalations to increase lung capacity and clear airways after surgery.19 These exercises are crucial in pulmonary rehabilitation programs as they not only improve lung function but also help individuals regain control over their breathing.

    The benefits of incorporating these exercises into rehabilitation are widely recognized. However, some people may face challenges in maintaining timing, frequency or focus on their breath during these exercises.20 Therefore, it is important to provide guidance that helps individuals maintain a breathing rhythm and awareness.

    Virtual Reality (VR) technology has made advancements in recent years bringing innovative solutions to various fields, including healthcare.21 With its interactive and immersive features, VR has the potential to revolutionize breathing exercises by making them engaging and enjoyable.22 Patients can be taken to tranquil settings for guided meditation, exciting adventures, or serene landscapes by combining therapeutic breathing exercises with engaging virtual environments and scenarios.23 This combination does not help distract patients from the nature of conventional exercises but also motivates them to actively participate potentially improving their adherence to rehabilitation routines. Furthermore, real time feedback and gamified elements provided by VR enable patients to track their progress and challenge themselves making the process of enhancing function not more effective but also more enjoyable.24

    VR offers an experience where patients actively participate in their rehabilitation creating a sense of presence and control. What sets VR apart is its ability to completely immerse users in environments making them feel like they are physically present in that world. This immersive nature of VR can be incredibly helpful in reducing stress and anxiety during breathing exercises.25 Many patients with conditions often feel anxious and uncomfortable due to the limitations imposed by their condition. Through the utilization of VR, patients can be sensory transported to serene and calming environments such as beaches, tranquil forests, or soothing meditation gardens. This immersive experience helps patients mentally escape from their discomforts and anxieties creating an atmosphere for effective breathing exercises and rehabilitation.25

    Moreover, the interactivity offered by VR brings a level of engagement.26 This means that patients can actively take part in their rehabilitation routines while immersed in a world often mimicking real life activities. For example, they can follow the instructions of an instructor as they engage in deep breathing exercises while observing how their avatar responds within the virtual environment. The ability to interact with objects and manipulate them within these spaces fosters a sense of control which can be particularly empowering for individuals undergoing rehabilitation.27

    In years, there has been a growing trend in utilizing VR to aid breathing exercise. However, there is lack of literature on how these exercises are currently incorporated into VR experiences making it challenging to evaluate their effectiveness. Particularly noteworthy is a scoping review that examines the current state of knowledge on this phenomenon. The only similar study that seems to have exist is Pancini et al study28 on the significance of VR breathing exercise in promoting mental health, while those on pulmonary rehabilitation is very limited. Additionally, it remains uncertain which rehabilitation outcomes have been accessed and whether these interventions yield results.

    Literature Review

    Virtual reality has grown increasingly common in healthcare intervention, notably in exercise and rehabilitation programs. The use of VR as a feasible tool for breathing exercises in rehabilitation has been examined. Numerous research has investigated the viability and efficiency of adopting VR in diverse contexts. In one study, patients with COPD employed immersive VR headsets as part of a high-intensity interval training (HIIT) exercise program.29 Twelve COPD patients took part in a six-week VR headset-based HIIT training as part of the study. Short bursts of high-intensity activity were alternated with rest or low-intensity exercise as part of the HIIT program. The patients were provided an immersive experience utilizing the VR headset, which lessened their feeling of effort and helped to inspire them. The feasibility and acceptability of VR-HIIT for COPD patients was determined by the authors. Without experiencing any serious side effects, the patients were able to conclude the HIIT program in a safe manner. Additionally, they noted that the VR experience was pleasurable and that it kept them motivated. The study’s findings show that VR-HIIT may be a novel and promising PR technique for COPD patients. Better patient results may arise from VR-HIIT’s capacity to increase desire and adherence to workout routines.

    Another study examined the acceptability and safety of a VR-based deep breathing exercise for kids and teenagers getting over a concussion.30 Concussion, categorized as a mild traumatic brain injury, triggers a series of pathophysiological changes and disruptions in brain function. These effects extend to various aspects of respiratory function, such as alterations in breathing rate, mechanics, and the levels of end tidal carbon dioxide.31 Thus, fifteen participants were recruited in the study from a specialty concussion clinic within a tertiary care medical center, aged 11 to 22, who had received a concussion in the previous three months. The participants used a VR headset to pace a 5-minute deep breathing exercise. They were introduced to a serene virtual world and educated in deep breathing strategies by the VR experience. Participants discussed their experiences and any changes in their symptoms following the activity. The outcomes demonstrated that the participants considered the VR-based deep breathing exercise to be both safe and well-tolerated. None of the participants quit the workout or complained of acute discomfort. Three individuals noticed a small increase in headache, nausea, or dizziness; however, these symptoms were simply transient and did not call for medical treatment.

    VR gaming and exergaming-based therapies were found to have weak to insignificant effects on heart rate and oxygen saturation in individuals with respiratory difficulties, and to have minor impacts on dyspnea, according to a systematic review and meta-analysis.32 Seventy-nine people with a range of respiratory conditions, such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD), participated in the evaluation’s 19 trials. The meta-analysis’s findings demonstrated that VR exercise helped people with respiratory disorders improve their quality of life, capacity for activity, and dyspnea. Although the effect sizes were statistically significant, they ranged from low to moderate. The authors concluded that VR exercise is a practical new approach to exercise therapy for those with respiratory issues.

    Furthermore, it was discovered that practicing breathing exercises with a VR system that offers multimodal biofeedback-including tactile and visual feedback-was both entertaining and successful.33 Twelve people took part in the study and used the VR equipment to conduct eight sessions of slow breathing exercises. The VR device guided the participants’ respiration with both physical and visual input. When they breathed appropriately, the participants could feel a slight vibration on their abdomen and view a virtual depiction of their own abdomen. The study’s findings demonstrated how well the multimodal VR system guided the participants’ deep, steady breathing. Following the completion of the slow breathing exercises, the participants’ breathing rate dramatically dropped. The VR system, according to the participants, improved the workouts’ motivation and enjoyment. The multimodal VR system is a viable and promising method of delivering slow breathing exercises, according to the research’s conclusion.

    The findings of these studies, collectively, demonstrate the immense potential of VR breathing exercises as a cutting-edge method for managing respiratory health and rehabilitation. Further research is required to examine the wider applicability and enduring impacts of VR breathing exercises, as well as to determine the most efficient VR therapies for specific medical conditions and demographics.

    Research Question

    This paper provides a scoping review of existing knowledge on the possibilities of integrating VR exercise in breathing rehabilitation. Therefore, this paper aim to provide answer to this research question: “Does VR Based Exercise Therapy Offer Significant Improvement in Patients/Participant Breathing rehabilitation/Function?”

    Materials and Methods

    Methodology

    Scoping reviews are undertaken with the purpose of delineating and examining emerging concepts within a particular field of research.34 In contrast to conventional systematic reviews that focus on narrower research issues and have a well-defined pool of relevant studies, scoping reviews are employed to explore emerging research domains and elucidate fundamental concepts.35

    Search Strategy and Study Selection

    Three electronic databases, including Web of Science, PubMed, and the Cochrane Library, were searched from October 28 to November 10, 2023. The query of the databases involves the use of the keywords “breathing rehabilitation, respiratory rehabilitation, virtual reality exercise, mixed reality exercise, and augmented reality exercise” to search their core collections. Following the search, citations were retrieved by the citation manager for reference management, while duplicate records were automatically excluded.

    Inclusion and Exclusion Criteria

    For this scoping review, articles were included without considering the specific research design. However, it is important to note that only studies involving human participants were considered, and studies involving animals were excluded from the review. articles published in English were included, and no English articles were excluded to avoid potential limitations associated with non-English papers. Specifically, the focus was on studies related to virtual reality exercise for breathing or respiratory rehabilitation, while studies outside the scope of this review were excluded. There were no restrictions regarding the year of publication or geographic region. However, articles that did not directly address the review question were excluded. Additionally, it is important to note that rehabilitation other than breathing was not within the scope of this review. Conference papers, systematic reviews, notes, secondary studies, and other reviews were excluded, prioritizing primary and original studies. The focus was on studies aimed at breathing functions and exercise, without specific limitations on the patient’s or participant’s condition. The emphasis was on including studies that directly contributed to the enhancement of breathing functions.

    Article Selection

    Following the retrieval of 236 citations from the databases, 42 duplicate records were removed automatically. The remaining data was then exported to Excel software version 12.0. The title and abstract of the articles were screened, and a total of 173 references were removed. The remaining 18 articles were subjected to full text screening to examine studies in line with the inclusion criteria and studies directly providing answers to the research. In this process, 10 articles not within the context of this research were excluded (Figure 1).

    Figure 1 Article screening flowchart.

    Quality Assessment

    The eight included studies were appraised to examine the methodological and reporting quality of these articles to rate the article’s risk of bias in planning, execution, and result presentation. In doing these, the Jonas Briggs Institute (JBI) checklist36 for randomized trials was utilized since all the studies were randomized trials37 (Appendix 1). The checklist contained 13 appraisal questions, but only applicable 10 questions were utilized. Articles are rated yes if they checked positive, no if they checked native, and unclear if they are unsure of whether they are positive or negative. At the end, overall ratings were based on %yes. Articles were considered high-quality if they scored 80% and above, moderate quality if they scored between 50% and 60%, and those below 50% were low quality and unfit for inclusion in this scoping review.

    Noteworthy, following the appraisal of the eight included articles, it was interesting to note that all the studies were of high quality and had a low risk of bias, with none of the papers scoring less than 80% Yes (Table 1). Notably, Rodrigues et al38 was the only study that checked positive for all the checklist questions with 100%. True randomization, allocation concealment, and similarity at baseline were positive across all the studies. Similarly, there was a proper record of follow-up, measures, and reliability, and appropriate statistical analysis was considered by all the included studies.

    Table 1 Quality Assessment of the Included Studies

    Data Extraction and Synthesis

    Information pertinent to this review objective was synthesized into a formulated Excel form, allowing a summary of each article’s information under various headings. The information extracted includes the corresponding author name, year of publication, country, journal, aim of the paper, sample characteristics, ie, demographic data, settings, patients, design, virtual reality system used, description of the system, measures, instrument, method of data collection and analysis, result, and main findings (Appendix 2).

    Moreover, the findings of the synthesis indicate that there has been a growing interest in the integration of virtual reality (VR) technology into breathing exercise program in recent years. As shown in Figure 2, there has been an increase in research in this domain.

    Figure 2 Article distribution by year.

    The publications included in the study came from five distinct countries, with the United States and Brazil emerging as the major contributors. Each of these countries provided two articles, making them the most significant contributors among the eight papers analyzed. Similarly, the Journal of Applied Psychophysiology and Biofeedback exhibited the greatest quantity of publications, whereas the remaining articles were published in the Asian Journal of Nursing, Journal of Physical Medicine and Rehabilitation, Journal of Personalized Medicine, Journal of Applied Psychophysiology and Biofeedback, Journal of Medical Internet Research, and Journal of BMC Psychiatry.

    Multiple convenient sample sizes were utilized, with an average sample size of 42 and a total sample size of 296. The sample population consists of individuals of both male and female genders, with a median age range spanning from 21.6 to 63.4 years. The individuals involved in the research were categorized as either in-patients or out-patients across the several investigations. The research involved patients or participants who shown a need to enhance their breathing functionality. All participants were randomly assigned to receive the VR-based intervention, and this assignment was conducted in accordance with relevant ethical consent procedures.

    Narrative Synthesis

    The study conducted by Kang et al39 in 2020 is the initial study included in the analysis, achieving a quality assessment score of 80%. The research utilized virtual reality technology to create an innovative breathing exercise solution that does not require contact with the mouth. Additionally, the study assessed the feasibility and effectiveness of this exercise technique. The proposed system is a virtual reality-based breathing exercise system, referred to as VR-BRES. The developers have integrated gaming features and a soft stretch sensor into their virtual reality-based self-regulatory biofeedback breathing workout system. The study assessed the feasibility and effectiveness of the system in comparison to the standard deep breathing (CDB) exercise. A total of 50 healthy participants (23 males and 27 females) with an average age of 42.52 ± 15.76 years were included in the analysis. The study involved individuals who were admitted as inpatients. Various respiratory parameters, such as forced vital capacity, forced expiratory volume in one second (FEV1), and peak expiratory flow (PEF), were assessed using a portable spirometry device called Pony FX (COSMED, USA). The utilization of the Virtual Reality-based Breathing Rehabilitation System (VR-BRES) yielded notable improvements in the parameters during the breathing rehabilitation program. Significantly, the outcomes of participants’ evaluations indicate that, in comparison to the standard deep breathing CDB exercise system, users regarded the breathing exercise with VR-BRES as more engaging, effective, and with a higher intention to utilize. Despite the lack of major differences in convenience across the various exercise approaches, However, the findings of the study indicate that virtual reality can serve as an effective training system for the purpose of respiratory rehabilitation.

    Blum et al study20 assessed the feasibility of utilizing a virtual reality exercise system for diaphragmatic breathing with the incorporation of biofeedback algorithms. The VR-based system also employs a respiratory biofeedback method. To assess the effectiveness of this system, a total of 72 participants, with a majority of 56 females and 16 males, were randomly assigned to engage in a brief VR-based breathing exercise. The average age of the participants was 21.6 years. The study involved a group of outpatients, and the variables assessed included participants’ post-exercise experience, subjective breath awareness after exercising, respiratory-induced abdomen motions during the exercise, and heart rate variability throughout the exercise. These measurements were obtained using the Oculus Rift CV1. In comparison to a control group engaging in focused breathing exercises, the findings of the study suggest that a VR-based breathing exercise system, when integrated with biofeedback, enhances respiratory sinus arrhythmias with a particular emphasis on slow diaphragmatic breathing. Similarly, enhancing breathing awareness and achieving an elevated level of user satisfaction.

    The study conducted by Betka et al40 focused on leveraging VR as a potential solution for addressing the issue of persistent dyspnea, often known as shortness of breath, among individuals in the recovery phase of COVID-19. The VR-based breathing workout system was utilized to construct a visual respiratory feedback function. The randomized experiment included a cohort of 26 participants, the majority of whom were male, with a median age of 55. The study involved individuals who were admitted as inpatients. The respiratory rate and respiratory rate variability were assessed as progression indicators of pulmonary rehabilitation. These parameters were recorded using the Go Direct® Respiration Belt, manufactured by Vernier, Beaverton, OR, USA. The intervention group was provided with synchronous feedback regarding their breathing, while the control group received asynchronous feedback. The assessment of the results was conducted using a combination of breathing recordings and questionnaires. The results of the trials suggest that the implementation of the Individual VR exercise system led to enhanced breathing comfort among participants in the intervention group, whereas no statistically significant improvements were observed in the control group. Although no negative effects were noted by the subjects, the research documented an increased level of user satisfaction and perception.

    Cruz and collaborators conducted a study41 in which various parameters were measured, including blood pressure, heart rate, respiratory rate (RR), peripheral oxygen saturation (SpO2), and rating of perceived exertion (RPE). These measurements were obtained utilizing the Epson PowerLite H309A and Xbox One Kinect devices. However, the study discovered that virtual reality-based therapy (VRBT) significantly enhances breathing rehabilitation by influencing various physiological parameters such as heart rate, respiratory rate, and rate of perceived exertion. These effects were observed during the execution of VRBT as well as during moments of rest and at 1, 3, and 5 minutes of recovery. The present study involved a cluster trail done at an outpatient rehabilitation center in Brazil, with a sample of 27 individuals with a mean age of 63.4 years.

    In a trial conducted by Ruzicky et al42 in which a pulmonary rehabilitation program, utilizing virtual reality technology to perform exercises, was provided to a group of 32 inpatient individuals diagnosed with COVID-19. The assessment included criteria such as breathing exercise tolerance and other factors. The findings from the trials indicate that the analysis of the initial data shown that a hospital-based pulmonary rehabilitation program lasting for a duration of three weeks resulted in enhanced exercise tolerance among those affected by COVID-19. Additionally, this program was associated with a decrease in symptoms related to depression and anxiety.

    Rodrigues et al38 similarly examine the potential impact of VR on the experience of dyspnea, as well as other factors including pain symptom management, well-being perception, anxiety, and depression, in a sample of 44 hospitalized individuals with COVID-19. The average age of the participants is 48.9, and the distribution of samples is equal between genders. A novel biofeedback VR breathing exercise, incorporating gaming elements and a lens, was created for the purpose of assessing dyspnea as the major outcome. Additionally, the secondary outcomes of arterial hypertension, heart rate, respiratory rate, and SpO2 were also evaluated. Upon completion of the studies, it is evident that exercise therapy utilizing VR has a substantial impact on reducing symptoms of dyspnea as well as other measurable secondary outcomes.

    A previous investigation conducted by Russell et al43 centered on the utilization of virtual reality to facilitate paced diaphragmatic breathing (DB) training. The study involved a randomized trial of 60 female outpatients who were assigned to receive a treatment consisting of VR-based breathing exercises. The study examined many outcomes, including heart rate variability, breathing rate, and assessments of motion nausea. It is important to note that heart rate variability is a controversial outcome measure herein. Heart rate variability is often used as an indicator of autonomic nervous system activity, specifically reflecting the balance between sympathetic and parasympathetic influences on heart rate. However, its interpretation as a direct measure of parasympathetic drive is subject to debate and caution. The study’s results indicate that the implementation of VR-based timed DB exercises leads to a notable enhancement in breathing functions and the activation of the parasympathetic nervous system (PNS). This activation of the PNS effectively mitigates physiological responses linked to motion sickness.

    In a study conducted by Shiban et al,44 the researchers examined the use of diaphragmatic breathing as a coping strategy in the context of virtual reality exposure therapy for aviophobia. The trial comprised a cohort of 29 individuals, with a significant majority being female. The measurement of both heart rate and respiration rate was conducted after the VR-exposure treatment. The findings indicate that the incorporation of VR technology into diaphragmatic breathing exercises yields enhancements in respiratory functions and aids in the alleviation of aviophobia.

    Discussion

    This research presents a scoping review that investigates the significance of integrating virtual reality exercise into breathing rehabilitation. Although different breathing techniques like mindful breathing, focused breathing, diaphragmatic breathing, and abdominal breathing are commonly used in clinical settings, there is a growing interest in exploring how emerging virtual reality technology could help with slow and controlled breathing, which could help with relaxation and improve respiratory functions.

    Based on the review of eight high-quality studies in this research, it is clear that VR technology has the potential to boost breathing function even more than traditional breathing exercises. This finding was corroborated by all of the trials included in the study. Of note, the majority of the reviewed papers relied on pilot studies or control studies as the basis for their research. Additionally, a subset of the papers focused solely on describing the design and development processes of their systems.

    Blum et al20 showed that a VR-based tool can work and be useful for encouraging slow diaphragmatic breathing through biofeedback of the respiratory system. The research conducted involved the development of a VR system for conducting breathing exercises. The study revealed how well a respiratory biofeedback method used in virtual reality could teach people how to control their breathing patterns and improve their overall respiratory health. It was quite interesting that the VR system developed in their paper facilitates the regulation of participants’ respiration through the utilization of visual stimuli. Showing each participant, a virtual representation of their chest cavity, wherein the color of the cavity changed in accordance with the depth of their breath further enhance participant breathing awareness. Upon the conclusion of multiple virtual reality training sessions, the participants acquired the ability to regulate their breathing patterns in a consistent and profound manner. This, however, facilitate the acquisition of improved breathing management skills, as a result of the biofeedback on their respiratory patterns. The findings of this study proved the feasibility and acceptability of utilizing VR for breathing rehabilitation and respiratory biofeedback.

    In contrast to different methods for breathing exercises, growing evidence and reports have consistently demonstrated the efficacy of the VR exercise system in enhancing breathing rehabilitation. This improvement is achieved through the utilization of the VR respiratory biofeedback technique, which not only offers participants an enjoyable and motivating experience but also provides them with valuable feedback on their breathing patterns. The observation of a notable rise in forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) after the VR-based breathing exercise training indicates the presence of this phenomenon. The integration of respiratory biofeedback techniques into the VR system in Blum study may presents a promising avenue for breathing rehabilitation, offering potential benefits offering potential benefits for individuals seeking to enhance their breathing capabilities. It was further underlined by the study that the advantages of VR can also be taken into account for several respiratory disorders, such as cystic fibrosis, COPD, and asthma, which may benefit from the technology.The link between success and the swift growth of VR breathing techniques may be attributed to the provision of a very engaging and immersive workout experience. All of the evaluated research consistently placed focus on these features. One of the studies,39 compared the efficacy and usefulness of a VR breathing exercise system to conventional deep breathing exercises. The findings of their trial indicated that although individual variations in breathing function exist, the use of a VR-based exercise system resulted in a noteworthy enhancement of breathing parameters. In-addition, their user reviews indicated that these training routines are highly captivating, enjoyable, and high intention to use.

    Similar to Blum’s findings, the fact that biofeedback and self-regulation are part of the virtual reality exercise system may explain the success of the breathing exercise system. This finding aligns with assertions made by other scholars, as its distinctiveness correlates to the visualization of respiratory signals that offers respiratory feedback. This was also emphasized by Kang et al VR-based breathing exercise system,39 which provides biofeedback through breathing signal visualization, such as the avatar rabbit jump. The importance of this biofeedback was also underscored in a prior study, which demonstrated that women with limited thoracic movement experienced notable changes in respiratory parameters when incorporating visual feedback of diaphragmatic motion through ultrasound imaging into their VR breathing exercise regimen. Significantly, the transformation of the physical expansion of the chest or abdomen during inhalation into visual cues that are promptly relayed to the participants was effectively augment and engagement in breathing exercises was heightened.

    The integration of bio-respiratory visual feedback into virtual reality exercise can also be utilized in addressing dyspnea38,40. In line with the findings of these authors, the inclusion of visual-respiratory feedback or self-regulating biofeedback in VR interventions may enhance the breathing comfort of patients in the recovery phase of COVID-19 pneumonia, particularly those who are experiencing persistent dyspnea. Betka et al further confirmed these through their clinical experiment, including patients who are undergoing recovery from COVID-19 and are persistently affected by dyspnea.40 The authors posited that in cases where alternative respiratory treatments or interventions prove ineffective and potentially result in serious complications such as cognitive impairments, mental health disorders, and motor impairments, the implementation of a virtual reality-based breathing exercise intervention could yield substantial success in addressing the issue of persistent dyspnea. This observation aligns with the findings of the Rodrigues et al study, wherein a significant decrease in dyspnea and fatigue was seen among those affected by COVID-19 following VR-based exercise intervention.38

    Virtual reality breathing exercise intervention demonstrates a broader impact beyond its application to COVID-19 patients. This claim was similarly supported by a recent study which indicated that VR tool can also effectively reduce tiredness and dyspnea in obstructive pulmonary patients via administering virtual reality-based pulmonary rehabilitation.45

    Additionally, a recent randomized control study conducted in Saudi Arabia (42) focused on children with repaired congenital diaphragmatic hernia (CDH), who are known to continue living with chronic lung issues and demonstrate lower cardiorespiratory fitness compared to their healthy counterparts. Consequently, there is a risk of declining functional performance and physical ability in these children due to reduced cardiopulmonary fitness. However, the study highlighted that when VR-based exercises are combined with traditional physical therapy, these children with repaired CDH experienced more significant improvements in their pulmonary functions, cardiopulmonary capacity, functional performance, and quality of life compared to those who received traditional physical therapy alone46. However, without a detailed explanation of the underlying mechanism of action, it is challenging to fully understand how VR-based exercises contribute to these positive outcomes. The absence of a conceptualized framework in several studies limits our ability to contextualize and interpret the study findings within a theoretical framework.

    This growing evidence among adults and kids supports the assertion that a VR-based breathing exercise system can be considered as a potential alternative approach which is non-invasive and has no pharmacological features for promoting the rapid recuperation of patients.

    This scoping review founds VR breathing exercise therapy to be a promising tool in terms of patient satisfaction and the potential to alleviate the breathing issues and persistent dyspnea commonly observed in individuals recovering from severe conditions like Covid-19. Clinical improvements were observed in various aspects as a result of the VR biofeedback breathing intervention. Participants demonstrated noteworthy improvements in fatigue levels, and overall comfort during breathing exercises. Moreover, positive alterations were observed in vital signs, encompassing heart rate and other cardiopulmonary parameters as reported by Betka et al.

    To show how fast these rehabilitation techniques can be, limited exposure of people having breathing problems to short synchronous VR interventions incorporating visuo-respiratory features may improve breathing comfort. The uniqueness of the Immersive VR developed by Betka and associates and the VR-assisted therapeutic breathing exercise system developed by Rodrigues et al underscores the importance of cardiac or respiratory synchrony and self-regulating biofeedback.38,40 This synchrony creates a system that offers a better outcome. For example, the utilization of a “virtual body that is animated by the patient’s own respiratory movements”, a “complete duration of the breathing sequence”, and a comparable “three-dimensional virtual environment” contribute to enhanced involvement in breathing exercises.

    The provision of synchronous feedback has been found to significantly enhance the perception of control among patients with respect to their respiratory function, as reported in multiple studies20,39,40. Consequently, this heightened sense of control contributes to the enhancement of breathing self-regulation and awareness. Although the initial stage of Betka’s study did not show a statistically significant decrease in breathing discomfort, it did reveal a notable improvement in overall breathing comfort when utilizing synchronous visuo-respiratory stimulation. The insignificant initial phase result may be attributed to semantics or subjective discomfort ratings. This claim is consistent with the findings of a study conducted recently on the effects of a virtual reality-based breathing therapy on physiological responses in breathing rehabilitation.41 Specifically, their findings indicated that this therapy is effective in conditioning the participants during the execution phase. However, it was noted that elevated levels of respiratory rate and other cardiac parameters may be achieved during the recovery phase, and these effects can persist for up to 5 minutes. It is not surprising that such interventions can have an impact on various hemodynamic functions during the recovery phase, even up to a few minutes after the activity has ended. Nevertheless, the diverse effects observed in their virtual reality breathing therapy may be attributed to the differential levels of effort and intensity applied during the treatment. These, however, raise the importance of exercising caution throughout the administration of the virtual reality intervention, particularly in terms of closely monitoring the level of virtual reality exertion.

    Betka40 and Cruz41 successfully demonstrated the safety and cost-effectiveness of immersive VR-based digital therapeutics and virtual reality breathing therapy. They posited that VR-based interventions can be utilized as alternative cardiovascular interventions for individuals who are either in-patients or out-patients and are facing respiratory or breathing challenges. This tool can offer a supplementary approach for treatment and assessment, thereby reducing the potential for transmission and mitigating the established adverse effects linked to opioid therapy.

    Additionally, this scoping review identified exercise tolerance; a key indicator of cardiovascular endurance during breathing rehabilitation, and the implications of optimal lung function as another important area in which VR can be leveraged. This was supported by Ruzicky et al investigation on the importance of VR in enhancing exercise tolerance.42 They emphasize incorporation of VR-breathing exercise rehabilitation into COVID-19 rehabilitation therapy due to its numerous advantages in enhancing respiratory problems. Their three-week VR pulmonary rehabilitation program for COVID-19 inpatients demonstrated a noteworthy effect, as patients exhibited notable improvements in exercise tolerance subsequent to exposure to VR breathing exercise. While there was a gain in functional ability, the improvement in quality of life was not found to be significant, and no notable advantage over conventional treatments was noted. This observation is in contrast with the conclusions drawn by previous researchers, who discovered a notable and distinct advantage of VR breathing exercises over traditional rehabilitation interventions.

    The preliminary nature of the data analysis in the their study42 and brief duration of the VR exposure may be attributed to the insignificance findings. Therefore, possibly conducting a re-evaluation with a more extensive sample size over long period of exposure could potentially yield a positive outcome. Despite these findings, the author asserts, in alignment with prior research, that the integration of VR into breathing rehabilitation therapy presents a viable approach for mitigating the long-term consequences of COVID-19 and other respiratory ailments.

    This review synthesizes evidence suggesting that VR breathing exercise interventions have the potential to yield more favorable outcomes compared to conventional interventions. Specifically, these interventions can effectively promote increased awareness of patients’ breathing status and facilitate the maintenance of a balanced pulmonary function. Moreover, VR exercise tool’s ability to provide entertainment, engagement, and interactivity aligns with its distinct advantage over usual exercise methods that entail passive exercise participation. This, however, leads users to see exercise, typically seen as a highly demanding activity, as an enjoyable and immersive experience owing to its interactive characteristics.

    In comparison to traditional breathing exercise interventions, a study conducted by Russell et al demonstrated that the diaphragmatic breathing protocol resulted in a drop-in respiration rate, an increase in parasympathetic nervous system tone, and a reduction in the occurrence of motion sickness symptoms.43 The objective of activating the parasympathetic nervous system, as indicated by an increase in heart rate variability, was successfully accomplished, potentially resulting in the prevention of symptoms associated with motion sickness. Furthermore, these findings provide additional support for the assertion that the utilization of VR breathing exercises might effectively mitigate the progression of symptoms associated with motion sickness resulting from breathing control. The confluence of diaphragmatic breathing mechanisms and reduced respiratory rate suggests that these methods have the potential to enhance parasympathetic tone and provide a safeguard against motion sickness when individuals are exposed to stimuli that induce motion sickness. Despite concerns regarding potential risks associated with diaphragmatic breathing exposure during VR exercise therapy, evidence suggests that diaphragmatic breathing during VR intervention does not moderate negative outcomes.44 On the contrary, it has been found to enhance the effectiveness of VR breathing exercise rehabilitation and alleviate conditions such as aviophobia, which involves a fear of flying.

    Considering the long-term effects is crucial for understanding the true potential and effectiveness of VR-based exercise interventions in the context of respiratory conditions. Future studies should address this limitation by incorporating follow-up evaluations to provide a more comprehensive understanding of the treatment’s lasting impact.

    Limitation and Conclusion

    Limitation

    The heterogeneous nature of the VR system and the biofeedback mechanisms and techniques employed by the different included studies may be considered the main limitations of this scoping review. Since the primary objective of each respective study varies, the outcome may vary with studies. Limited numbers of trials may also be a potential limitation, as it is difficult to conclude with limited evidence. Nonetheless, the scoping review of eight quality studies in these current papers confirmed the significance of taking advantage of VR in breathing exercise rehabilitation.

    It is noteworthy that the findings of some reported studies exhibit variability due to factors such as constraints in experimental design methodology, inadequate availability of objective measurable breathing outcomes, and limited sample sizes. We encourage readers to conduct a more critical appraisal of the article/topic(s) of interest to form an independent and informed judgment regarding the effectiveness and implications of breath training with/without the VR in the context of their specific clinical population.

    Conclusion

    The effectiveness and rapid growth of VR breathing techniques are attributed to their engaging and immersive experience. The integration of biofeedback and self-regulation in VR exercise systems was also found to contribute to the significant outcome of the breathing exercise system. This is because the use of visual feedback in VR breathing exercises enhances user interest in breathing exercises.

    In addition, this scoping review highlights the effectiveness of VR exercise in improving dyspnea, a breathing condition. The unique aspect of VR-assisted breathing exercise systems lies in their emphasis on cardiac or respiratory synchrony and self-regulating biofeedback. The inclusion of a “virtual body animated by the patient’s own breathing” and a 3D virtual environment enhances engagement, self-regulation, and awareness during breathing exercises. However, the review also indicates that the outcomes of VR rehabilitation can vary depending on the effort and intensity exerted. Therefore, careful monitoring of VR effort intensity is necessary. Overall, VR breathing exercises are considered safe and cost-friendly rehabilitation tools for both in-patients and out-patients with respiratory difficulties.

    Additionally, the paper suggests that VR breathing exercise interventions offer preventive measures against the prolonged effects of conditions such as COVID-19 and other respiratory conditions. These interventions motivate patients to be mindful of their breathing condition and maintain balanced pulmonary function. The entertaining, engaging, and interactive nature of VR exercise therapy adds a fun and immersive element to the overall exercise experience for users.

    Abbreviations

    COPD, chronic obstructive pulmonary disease; CDH, congenital diaphragmatic hernia; DB, diaphragmatic breathing; FEV1, forced expiratory volume in one second; HIIT, high-intensity interval training; JBI, Jonna Briggs Institute; VR, virtual reality; VRBT, virtual reality-based therapy; PNS, parasympathetic nervous system; PR, Pulmonary rehabilitation.

    Acknowledgments

    The author would like to thank the College of Applied Medical Sciences Research Center and the Deanship of Scientific Research at King Saud University.

    Disclosure

    The author reports no conflicts of interest in this work.

    References

    1. Pleil JD, Ariel Geer Wallace M, Davis MD, Matty CM. The physics of human breathing: flow, timing, volume, and pressure parameters for normal, on-demand, and ventilator respiration. J Breath Res. 2021;15(4):042002. doi:10.1088/1752-7163/ac2589

    2. Nelson N. Diaphragmatic breathing: the foundation of core stability. Strength Conditioning J. 2012;34(5):34–40. doi:10.1519/SSC.0b013e31826ddc07

    3. Pawaria S. Breathing- mechanism of breathing, muscles of respiration, breathing pattern and breathing exercises. In: DrTM A, editor. Emerging Trends in Disease and Health Research Vol. 6. Book Publisher International (a Part of SCIENCEDOMAIN International). 2022:128–141. doi:10.9734/bpi/etdhr/v6/15350D

    4. Lu HB, Ma RC, Yin YY, Song CY, Yang TT, Xie J. Clinical indicators of effects of yoga breathing exercises on patients with lung cancer after surgical resection: a randomized controlled trial. Cancer Nurs. 2023. doi:10.1097/NCC.0000000000001208

    5. Kader M, Hossain M, Reddy V, Perera NKP, Rashid M. Effects of short-term breathing exercises on respiratory recovery in patients with COVID-19: a quasi-experimental study. BMC Sports Sci Med Rehabil. 2022;14(1):60. doi:10.1186/s13102-022-00451-z

    6. Gerage AM, Alberton CL, Cucato GG, Delevatti RS, Ritti-Dias RM. Editorial: exercise intervention for prevention and management of hypertension. Front Physiol. 2023;14:1244715. doi:10.3389/fphys.2023.1244715

    7. Hopper SI, Murray SL, Ferrara LR, Singleton JK. Effectiveness of diaphragmatic breathing for reducing physiological and psychological stress in adults: a quantitative systematic review. JBI Database Syst Rev Implement Rep. 2019;17(9):1855–1876. doi:10.11124/JBISRIR-2017-003848

    8. Cai Y, Ren X, Wang J, Ma B, Chen O. Effects of breathing exercises in patients with chronic obstructive pulmonary disease: a network meta-analysis. Arch Phys Med Rehabil. 2023;S0003999323002836. doi:10.1016/j.apmr.2023.04.014

    9. Martins A, Arienzo A. Experiences and preferences of persons with asthma regarding breathing exercises are more related to wellness than to healthcare. Pneumologie. 2023;77(S 01):Po–436. doi:10.1055/s-0043-1761127

    10. Hussein EE, Taha NM. Effect of breathing exercises on quality of recovery among postoperative patients. Int J Stud Nurs. 2018;3(3):151. doi:10.20849/ijsn.v3i3.525

    11. Gholamrezaei A, Van Diest I, Aziz Q, Vlaeyen JWS, Van Oudenhove L. Psychophysiological responses to various slow, deep breathing techniques. Psychophysiology. 2021;58(2):e13712. doi:10.1111/psyp.13712

    12. Apriliana D, Suradi S, Setijadi AR. Role of incentive spirometry on exercise capacity, breathing symptoms, depression rate, and quality of life in NSCLC patients with chemotherapy. Respir Sci. 2021;2(1):8–17. doi:10.36497/respirsci.v2i1.33

    13. Suharti A, Rachmawati Nur Hidayati E, Yusviani HA. Comparative effect of incentive spirometry and diaphragm breathing to functional capacity in COVID-19 patient in an isolated ward. Bali Med J. 2022;11(3):1415–1419. doi:10.15562/bmj.v11i3.3579

    14. Wang YQ, Cao HP, Liu X, et al. Effect of breathing exercises in patients with non-small cell lung cancer receiving surgical treatment: a randomized controlled trial. Eur J Integr Med. 2020;38:101175. doi:10.1016/j.eujim.2020.101175

    15. Arden-Close E, Teasdale E, Tonkin-Crine S, et al. Patients’ perceptions of the potential of breathing training for asthma: a qualitative study. Prim Care Respir J. 2013;22(4):449–453. doi:10.4104/pcrj.2013.00092

    16. Morrow B, Brink J, Grace S, Pritchard L, Lupton-Smith A. The effect of positioning and diaphragmatic breathing exercises on respiratory muscle activity in people with chronic obstructive pulmonary disease. South Afr J Physiother. 2016;72(1):6. doi:10.4102/sajp.v72i1.315

    17. Lee K, Choo Y-KI. Inspiratory muscle strengthening training method to improve respiratory function: comparison of the effects of diaphragmatic breathing with upper arm exercise and power-breathe breathing. J Korean Soc Integr Med. 2021;9(3):201–211. doi:10.32625/KJEI.2021.24.201

    18. Yang Y, Wei L, Wang S, et al. The effects of pursed lip breathing combined with diaphragmatic breathing on pulmonary function and exercise capacity in patients with COPD: a systematic review and meta-analysis. Physiother Theory Pract. 2022;38(7):847–857. doi:10.1080/09593985.2020.1805834

    19. Kotta PA, Ali JM. Incentive spirometry for prevention of postoperative pulmonary complications after thoracic surgery. Respir Care. 2021;66(2):327–333. doi:10.4187/respcare.07972

    20. Blum J, Rockstroh C, Göritz AS. Development and pilot test of a virtual reality respiratory biofeedback approach. Appl Psychophysiol Biofeedback. 2020;45(3):153–163. doi:10.1007/s10484-020-09468-x

    21. Kouijzer MMTE, Kip H, Bouman YHA, Kelders SM. Implementation of virtual reality in healthcare: a scoping review on the implementation process of virtual reality in various healthcare settings. Implement Sci Commun. 2023;4(1):67. doi:10.1186/s43058-023-00442-2

    22. Miner N. Stairway to Heaven: Breathing Mindfulness into Virtual Reality. Northeastern University; 2022. doi:10.17760/D20471083

    23. Li S, Zheng H, Ge Y, Yuan W, Han T Designing mindfulness practice system based on biofeedback in VR environment. In: Volume 2: 42nd Computers and Information in Engineering Conference (CIE). American Society of Mechanical Engineers; 2022:V002T02A090. doi:10.1115/DETC2022-91254.

    24. Subramanian SK. Virtual reality in rehabilitation—using technology to enhance function. Pm&r. 2018;10(11):1221–1222. doi:10.1016/j.pmrj.2018.11.001

    25. Li BJ, Peña J, Jung Y. Editorial: VR/AR and wellbeing: the use of immersive technologies in promoting health outcomes. Front Virtual Real. 2023;3:1119919. doi:10.3389/frvir.2022.1119919

    26. Dar S, Ekart A, Bernardet U The virtual human breathing coach. In: 2022 IEEE Conference on Virtual Reality and 3D User Interfaces Abstracts and Workshops (VRW). IEEE; 2022:434–436. doi:10.1109/VRW55335.2022.00095.

    27. Freeman D, Reeve S, Robinson A, et al. Virtual reality in the assessment, understanding, and treatment of mental health disorders. Psychol Med. 2017;47(14):2393–2400. doi:10.1017/S003329171700040X

    28. Pancini E, Anna FDN, Villani D. Breathing in virtual reality for promoting mental health: a scoping review. Preprint. 2023;1–43.

    29. Hoeg ER, Bruun-Pedersen JR, Serafin S Virtual reality-based high-intensity interval training for pulmonary rehabilitation: a feasibility and acceptability study. In: 2021 IEEE Conference on Virtual Reality and 3D User Interfaces Abstracts and Workshops (VRW). IEEE; 2021:242–249. doi:10.1109/VRW52623.2021.00052.

    30. Cook NE, Huebschmann NA, Iverson GL. Safety and tolerability of an innovative virtual reality-based deep breathing exercise in concussion rehabilitation: a pilot study. Dev Neuro Rehabil. 2021;24(4):222–229. doi:10.1080/17518423.2020.1839981

    31. Snyder A, Sheridan C, Tanner A, et al. Cardiorespiratory functioning in youth with persistent post-concussion symptoms: a pilot study. J Clin Med. 2021;10(4):561. doi:10.3390/jcm10040561

    32. Condon C, Lam WT, Mosley C, Gough S. A systematic review and meta-analysis of the effectiveness of virtual reality as an exercise intervention for individuals with a respiratory condition. Adv Simul. 2020;5(1):33. doi:10.1186/s41077-020-00151-z

    33. Lan KC, Li CW, Cheung Y. Slow breathing exercise with multimodal virtual reality: a feasibility study. Sensors. 2021;21(16):5462. doi:10.3390/s21165462

    34. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. doi:10.1080/1364557032000119616

    35. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Health. 2015;13(3):141–146. doi:10.1097/XEB.0000000000000050

    36. Barker TH, Stone JC, Sears K, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023;21(3):494–506. doi:10.11124/JBIES-22-00430

    37. Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Chapter 3: systematic reviews of effectiveness. JBI Manual for Evidence Synthesis. 2020;3. doi:10.46658/JBIMES-20-04

    38. Rodrigues IM, Lima AG, Santos AED, et al. A single session of virtual reality improved tiredness, shortness of breath, anxiety, depression and well-being in hospitalized individuals with COVID-19: a randomized clinical trial. J Pers Med. 2022;12(5):829. doi:10.3390/jpm12050829

    39. Kang J, Hong J, Lee YH. Development and feasibility test of a mouth contactless breathing exercise solution using virtual reality: a randomized crossover trial. Asian Nurs Res. 2021;15(5):345–352. doi:10.1016/j.anr.2021.12.002

    40. Betka S, Kannape OA, Fasola J, et al. Virtual reality intervention alleviates dyspnoea in patients recovering from COVID-19 pneumonia. ERJ Open Res. 2023;9(6):00570–02022. doi:10.1183/23120541.00570-2022

    41. Alves Da Cruz MM, Ricci-Vitor AL, Bonini Borges GL, Fernanda Da Silva P, Ribeiro F, Marques Vanderlei LC. Acute hemodynamic effects of virtual reality–based therapy in patients of cardiovascular rehabilitation: a cluster randomized crossover trial. Arch Phys Med Rehabil. 2020;101(4):642–649. doi:10.1016/j.apmr.2019.12.006

    42. Ruzicky E, Sramka M, Sramka M, et al. Providing prevention, diagnosis, and treatment of patients after COVID-19 using artificial intelligence. Neuro Endocrinol Lett. 2022;43(1):9–17.

    43. Russell MEB, Hoffman B, Stromberg S, Carlson CR. Use of controlled diaphragmatic breathing for the management of motion sickness in a virtual reality environment. Appl Psychophysiol Biofeedback. 2014;39(3–4):269–277. doi:10.1007/s10484-014-9265-6

    44. Shiban Y, Diemer J, Müller J, Brütting-Schick J, Pauli P, Mühlberger A. Diaphragmatic breathing during virtual reality exposure therapy for aviophobia: functional coping strategy or avoidance behavior? A pilot study. BMC Psychiatry. 2017;17(1):29. doi:10.1186/s12888-016-1181-2

    45. Jung T, Moorhouse N, Shi X, Amin MF. A virtual reality–supported intervention for pulmonary rehabilitation of patients with chronic obstructive pulmonary disease: mixed methods study. J Med Internet Res. 2020;22(7):e14178. doi:10.2196/14178

    46. Azab AR, Elnaggar RK, Abdelbasset WK, et al. Virtual reality-based exercises’ effects on pulmonary functions, cardiopulmonary capacity, functional performance, and quality of life in children with repaired congenital diaphragmatic hernia. Eur Rev Med Pharmacol Sci. 2023;27(14):6480–6488. doi:10.26355/eurrev_202307_33118

    Source link

    We suggest a “back to basics” approach to treating lung disease in Indigenous people in the Top End by making best use of limited resources, as shown in our recent study that used a simple chest x-ray and spirometry.

    Associate Professor Ford’s mother Nancy Daiyi used to describe her health as “Ngu.ngook tjan!”.

    The English translation is “I am short wind” meaning she was out of breath and finding it difficult to breathe. The Indigenous people in Australia believe that the spiritual and emotional wellbeing of body is connected to the wind – “the lungs”. To be “short wind” is to represent sickness and “good wind” means “I’m alive and well” (here). Sadly, in a high income country such as Australia, the story of “short wind” continues to be highly prevalent among Indigenous Australians with chronic lung diseases. We still have a health equity gap to bridge to the “good wind” story. Almost one in three Indigenous Australians self-report current long term respiratory disease, and hospitalisation rates for respiratory diseases are 2.4 times higher in Indigenous Australians compared with their non‑Indigenous counterparts (here).

    The age-standardised rate of deaths from respiratory disease, shown below in Figure 1, has changed very little over the past decade (2010–2019). Part of the systemic failure to address the disparity in respiratory health outcomes may be due to the lack of relevant and appropriate data collection and respiratory research funding allocations in the past.

    Our basic understanding of lung health is lacking; that is, normative lung function values in Indigenous adults, chest radiology data, guidelines on diagnosis and disease classifications, therapeutic guidelines and interventions specific for Indigenous adults. Understandably, this gives rise to diagnostic and management challenges in day-to-day clinical practice.

    Moreover, due to the lack of Indigenous-specific diagnostic and management guidelines, health practitioners inevitably adopt the established non-Indigenous management practices, which may not necessarily be appropriate. Our research from Flinders University and Charles Darwin University, Northern Territory (NT), has highlighted lung health issues among adult Indigenous patients in the Top End region of the NT of Australia in the past five years, and has demonstrated how different chronic respiratory diseases manifest in Indigenous people compared with non-Indigenous people, which is of interest for health organisations and all community stakeholders.

     - Featured Image
    Figure 1. Rate of hospitalisations (2009–10 to 2018–19) and deaths (2010–2019) due to respiratory disease, by Indigenous status (age-standardised). Source: www.indigenoushpf.gov.au

    What does the research demonstrate?

    In addition to common lung conditions such as asthma, bronchiectasis and chronic obstructive pulmonary disease (COPD), uncommon, advanced and complex concurrent lung conditions are highly prevalent in Indigenous people (here, here and here). Indigenous adults typically present with chronic respiratory disorders at a much younger age, with a marginally higher prevalence in remote compared with urban areas, and die younger (here, here and here). “Short wind” — shortness of breath — is one of the most common presenting symptoms (here).

    To date, lung function (spirometry) reference norms have not been well established for Indigenous adults. This raises a fundamental question: if we do not know what is normal, how are we going to say what is abnormal? Our studies have shown that, when adopting lung function reference norms based on people of European ancestry, even apparently healthy Indigenous adults may be 20% lower and only 10–12% lie in the normal range. Indigenous adults’ lung function parameters also do not match any published ethnic populations (here and here).

    Hence, there are challenges imposed in the accurate diagnosis and severity classification of lung disease in Indigenous people. Indeed, our research has demonstrated that the majority of Indigenous patients with COPD will be classified to have severe airway disease if using reference norms based on people of European ancestry (here).

    Another study has shown significant differences in the manifestation of COPD in Indigenous people in comparison to non-Indigenous people (here). Hence, by applying current guidelines in the management of patients with COPD, many may be misclassified with the severity of lung disease, which could give way for potentially inappropriate treatment interventions, more specifically in the use of inhaled directed airway therapy.

    Studies from the Top End have shown the concurrent presence of COPD and bronchiectasis are highly prevalent in Indigenous people (here and here). Although both conditions share similar clinical features, the management is different, especially when considering inhaled corticosteroids. Inhaled corticosteroids are recommended to be used with caution in patients with bronchiectasis. A study from the Top End has shown marked decline in lung function parameters among a proportion of patients using inhaled corticosteroids with bronchiectasis (here and here).

    Although the prevalence of asthma among Indigenous Australians is portrayed to be highest in the world, much higher than their non-Indigenous counterparts, studies exploring the prevalence may have had methodological flaws by utilising patients’ recall of a past asthma diagnosis.

    However, an NT study has illustrated that patients’ knowledge on their lung condition is extremely poor (here). Our study from the Top End has shown when using objective measures of accurate asthma diagnosis, the rates of asthma are not any different in Indigenous people compared with their non-Indigenous counterparts (here).

    From “short wind” to “good wind”: fighting chronic lung disease in Indigenous Australians - Featured Image
    Recent studies have demonstrated a high burden of respiratory conditions, with multiple advanced and complex chest imaging findings (bendao / Shutterstock).

    Until recently, there has been an unprecedented gap in our knowledge in relation to chest radiology data among Indigenous adults. Recent studies have demonstrated a high burden of respiratory conditions, with multiple advanced and complex chest imaging findings, including the presence of cystic lung disease and mediastinal lymph node disease (here, here, here and here). Furthermore, the use of common recreational substances can have catastrophic effects in this setting, as recently described in a case series of using cannabis via “bucket bong” (the “bucket bong” lung) (here).

    Another recent study from the Top End has demonstrated for the first time that lung nodules are an extremely common chest radiology finding, yet the majority are benign (here). Data on lung nodules and malignancy are limited in Indigenous populations. To add to the complexity, remotely residing Indigenous people often have severe obstructive sleep apnoea, and acceptance of modern treatment intervention devices such as continuous positive airway therapy (CPAP) is challenging (here and here).

    Sadly, literature addressing pleural effusion among Indigenous patients is almost non-existent other than a single study from the NT demonstrating one of the most common causes for pleural effusion in this population is secondary to chronic renal disease, which is also highly prevalent (here).

    The future

    Rates of chronic lung disease disparity in health outcomes, lack of equity and the failure of the closing the gap initiatives in the ongoing morbidity and mortality among Indigenous adults are likely to stay the same for the foreseeable future until and unless drastic actions are undertaken. The rhetoric now is how and where to from here in the quest to close the lung health gap?

    It is critical that health practitioners are aware of the differing demographic and clinical manifestations of chronic lung disease in Indigenous people compared with non-Indigenous people. We argue that further research should focus on gathering clinical data, normative spirometry reference values and radiology data. Indigenous-specific guidelines for appropriate diagnosis, classification and management of chronic airway disease are paramount.

    Indigenous-specific lung cancer screening pathways; robust smoking cessation programs, including ill effects of cannabis use; provision of regular physiotherapy services for airway clearance; and education to empower patients to take responsibility for their health are required. This will not be achievable unless there is a shift in relevant health organisations, stakeholders and, more importantly, research funding bodies to engage and support Indigenous health workers and practitioners in regional and rural communities for clinician-led research to address realistic needs.

    Until then, we suggest a “back to basics” approach by making the best use of limited resources to aid in the appropriate management of respiratory disorders in remote Indigenous communities. As demonstrated in a recent study, utilising simple chest x-ray and spirometry has fair sensitivity and specificity in the accurate diagnosis of chronic airway disease (here).

    Although we have demonstrated several aspects of the respiratory health burden in Indigenous people, including issues relating to pulmonary function testing and appearances on chest computed tomography (CT) and endpoint datasets, much more work remains to be done. The Australian Government-approved Lung Cancer Screening Program and co-design work, with a collaborate yarning methodology, working with National Aboriginal Community Controlled Health Organisation (NACCHO), is in progress, with a fully funded low dose chest CT Lung Cancer Screening Program set to commence in 2025 (here, here and here).

    We have to wait and see if this work may shed more light on respiratory health burden in the wider community of Indigenous Australians to reduce the disparity in respiratory health.

    Associate Professor Subash S Heraganahally is the Head of the Department of Respiratory and Sleep at the Royal Darwin Hospital, Director of Darwin Respiratory and Sleep Health at Darwin private hospital and an Associate Professor in the College of Medicine and Public Health at Flinders University.

    Dr Timothy Howarth is a Researcher for Darwin Respiratory and Sleep Health at Darwin private hospital and a Post-Doctoral researcher in the Sleep Technology and Analytics Research group at the University of Eastern Finland.

    Associate Professor Linda Ford is a Mak Mak Marranunggu woman from the Northern Territory, and a Senior Research Fellow in the Northern Institute, Charles Darwin University.

    Dr Lisa Sorger is the Chief Medical Officer for Integral Diagnostics and Consultant Radiologist at Apex Radiology Western Australia.   

    The statements or opinions expressed in this article reflect the views of the authors and do not necessarily represent the official policy of the AMA, the MJA or InSight+ unless so stated. 

    Subscribe to the free InSight+ weekly newsletter here. It is available to all readers, not just registered medical practitioners. 

    If you would like to submit an article for consideration, send a Word version to [email protected]. 

    Source link

    With Friday marking the second annual International Long COVID Awareness Day, Michigan House Speaker Joe Tate (D-Detroit) and Rep. Tyrone Carter (D-Detroit) paid a visit to a mobile health unit that has been providing Detroit residents with free screenings experiencing respiratory issues after a COVID-19 infection. 

    The mobile health unit opened in December through a partnership between People.Health, Moderna, Team Wellness Center and other community organizations to offer individuals no-cost CT screenings looking for lung damage from risk factors including Long COVID.

    Partnerships like this one have been key in bringing health care resources into communities that may not have a clinic or hospital, Tate said. 

    How Long COVID has become the ‘silent pandemic’

    “It seems like a lifetime since we’ve been dealing with COVID, but it’s only really been four years that we’ve been handling it, so, you know, having these partnerships with Moderna, Team Wellness, and other community partners is incredibly critical,” Tate said.

    In April 2020, Michigan established its COVID-19 Racial Disparities Task Force, aimed at addressing the disproportionate number of COVID-19 cases and mortality among Black residents.

    While the task force helped successfully close the racial gap in COVID-19 cases and deaths, its health equity work continued beyond the pandemic supporting improved access to health care and telehealth, through efforts including mobile health units. 

    In the state general government budget for Fiscal Year 2024, Michigan allocated $7 million to support the development of mobile health units, which are used to fill gaps in access to health care services. The inclusion of this funding came at the recommendation of the task force

    In addition to providing pathways for people to receive support, partnering with trusted community organizations may help overcome some individual’s resistance to seeking care, Tate said. 

    Phillip Levy, People.Health’s chief medical officer, said delivering place-based and accessible medical services is critical, especially in addressing Long COVID concerns.

    “You have a lot of underserved members of the community who may have been experiencing persistent symptoms after COVID, shortness of breath, fatigue, what have you,” Levy said. “They’ll go to their doctor or they’ll go to an urgent care and people will say, ‘Hey, there’s really nothing we can do, there’s nothing wrong.’”

    Across the nation, an estimated 17.5 million people currently have Long COVID, with data from the U.S. Census Bureau’s Household Pulse Survey finding more than 17% of adults in Michigan have experienced Long COVID.

    “If you do have ongoing damage in your lungs and you have other problems related to your COVID, it’s important to know and it’s important to, you know, see what things might be able to mitigate it,” Levy said. 

    While the focus of the screenings is to address lung damage from COVID-19. these screenings have been beneficial in uncovering a range of other conditions. 

    “We’ve picked up a number of cancers already. People who’ve had thyroid nodules and it turned out to be thyroid cancer would never have known,” Levy said. “We had a gentleman early on who came through, had a big mass blocking his stomach, was losing 30 pounds over the last month, would never have known this,” Levy said. 

    The screenings have also detected lung nodules, which can be a sign of lung cancer, and high amounts of coronary calcium which is one of the most important indicators of early-onset coronary heart disease, the leading cause of death in the country, Levy said. 

    “If we can detect this and get people in for screening, and encourage them before they get symptoms, maybe they’re not going to drop dead of a heart attack, and that’s what we want,” Levy said. 

    These screenings have also allowed Moderna and People.Health to study how lungs function following Long COVID outcomes, said James Mansi, vice president of medical affairs for the United States at Moderna. 

    A mobile health unit offering free CT screenings parked outside Team Wellness Center in Eastern Market in Detroit. | Kyle Davidson

    “That’s going to shed an important piece of light around our understanding of the impact that COVID has had on lung function. But to get to that we need to bring that awareness around maintaining one’s health, about screening, and part of that is this lung CT,” Mansi said. 

    “So we’re working with the community, getting them involved, and at the same time asking them ‘Well, would you be interested in participating in a research study looking at lung function, following COVID,’” Mansi said. 

    More than 94% of individuals have agreed to participate in these trials, which speaks to the trust that these organizations have built with their community, Mansi said. 

    Following the screening People.Health will contact people with their results, and if there is a finding, they will be instructed to contact their primary care provider. If they do not have a provider, Team Wellness Center provides primary care and will follow up, said Dani Hourani, Team Wellness Center’s director of community development. 

    “We are more than willing [and] able to be a partner and assist anybody. We will get them into an appointment right away and get them situated and set up with the specialist that they might need,” Hourani said. 

    “It’s not just about getting a screening and handing you your results and saying good luck. We want to make sure there’s the follow up part. What can we do to help you and your next steps and your healing,” Hourani said.

    Source link

    Public health news: March 2024

    People who smoke in South Tyneside are being encouraged to put smoking behind them this No Smoking Day (13 March 2024) for better health, more money and less stress.

    People are being encouraged to make a fresh quit and visit www.FreshQuit.co.uk for tips, advice and local quit support.

    There are lots of reasons to make a quit attempt and go smokefree:

    • Feel healthier: easier breathing, fewer coughs and colds and less risk of a diseases such as cancer, heart attack, stroke and COPD.
    • Practice makes perfect: if you've tried before, you can learn from what worked and what didn't. Treat previous tries as a stepping stone.
    • More money: quitting smoking will give you money you didn't know you had, another £47 a week or £2400 a year.
    • Less stress: quitting smoking is proven to leave people feeling calmer and happier after a few weeks. Using quit aids, nicotine replacement or a vape can help ease any cravings while you quit.
    • Quitting smoking makes it less likely your children will smoke.

    South Tyneside is supporting the Smoking Survivors campaign from Fresh in the run up to this year's No Smoking Day on Wednesday 13 March 2024. The annual No Smoking Day campaign is now in its 40th year.

    Ailsa Rutter OBE, Director of Fresh and Balance, said: "No Smoking Day is another great opportunity to give quitting a go. However you quit smoking it's a good way - whether that's using a quit aid, getting support or switching to vaping. Easing cravings can take a lot of the stress out of quitting.

    Our Smoking Survivors campaign has helped thousands of people to move closer to quitting smoking. Even if you have tried to quit before, why not make a fresh quit - this time it can be different."

    It can take a number of attempts to successfully stop for good, but there are lots of ways to stop which can take a lot of the stress out of quitting.

    Your chances improve if you use a quitting aid or switch completely to vaping to reduce cravings. Stop Smoking Services can also help you develop a plan to help you stop for good. 

    Here's how your body recovers when you quit:

    After 20 minutes

    Your pulse rate starts to return to normal.

    After 8 hours   

    Your oxygen levels are recovering, and the level of harmful carbon monoxide in your blood will have reduced by half.

    After 48 hours

    All carbon monoxide is flushed out. Your lungs are clearing out mucus and your senses of taste and smell are improving.

    After 72 hours

    If you notice that breathing feels easier, it's because your bronchial tubes have started to relax. Also your energy will be increasing.

    After 2 to 12 weeks

    Blood will be pumping through to your heart and muscles much better because your circulation will have improved.

    After 6 weeks

    Smokers who stop have better mental health than those who continue to smoke. One study found that benefits could be seen as soon as six weeks and were maintained even a number of years after stopping.

    After 3 to 9 months

    Any coughs, wheezing or breathing problems will be improving as your lung function increases.

    After 1 year

    Great news: Your risk of heart attack will have halved compared with a smoker's.

    After 10 years

    Your risk of death from lung cancer will have halved compared with a smoker's.

    Source: www.nhs.uk/better-health/quit-smoking/

    Smoking in Pregnancy

    Quitting smoking is one of the best things you can do if you're having a baby.

    The sooner you stop smoking, the better it is for you and your baby.

    Nicotine is very addictive so it's really important to get the right support to help you quit.

    We're offering Nicotine Replacement Therapy and Love2Shop vouchers with free support from a trained adviser to help give pregnant women the best chance to quit smoking for good.

    You can choose to do this in the hospital or at a local Family Hub.

    We can support your partner or other family members to quit too.

    If you're pregnant, stopping smoking is the best thing you can do. Quitting smoking now you are pregnant has lots of benefits to you and your baby.

    You will reduce your risk of:

    • Miscarriage
    • Premature birth
    • StillbBirth
    • Sickness during pregnancy
    • Heart disease
    • Cancer

    You will reduce the risk to your baby of:

    • A low birth weight
    • Asthma
    • ADHD
    • Colic
    • Ear infections
    • Respiratory infections
    • SIDS (Sudden Infant Death Syndrome)

    Speak to your midwife to find out more about getting help to quit smoking during your pregnancy.

    Source link

    The Mektovi dosage your doctor prescribes will depend on several factors. These include:

    • other medical conditions you may have, such as liver problems
    • how well your body tolerates Mektovi treatment

    The following information describes dosages that are commonly used or recommended. However, be sure to take the dosage your doctor prescribes for you. Your doctor will determine the best dosage to fit your needs.

    Drug forms and strengths

    Mektovi comes as an oral tablet. It’s available in one strength of 15 milligrams (mg).

    Dosage for melanoma

    Mektovi is prescribed to treat melanoma in certain adults. For this use, the recommended dose is 45 mg. You’ll take this dose twice daily, approximately 12 hours apart.

    You’ll continue taking this dosage for as long as you and your doctor determine Mektovi is safe and effective for you. However, if you develop certain side effects, your doctor may pause your treatment or reduce your dosage. This depends on how severe the side effects are and how long it takes for the side effects to ease or go away.

    For this use, Mektovi is prescribed in combination with encorafenib (Braftovi). If your doctor recommends stopping Braftovi, you’ll also stop Mektovi.

    Dosage for metastatic non-small cell lung cancer

    Mektovi is prescribed to treat non-small cell lung cancer in certain adults. For this use, the recommended dose is 45 mg. You’ll take this dose twice daily, approximately 12 hours apart.

    You’ll continue taking this dosage for as long as you and your doctor determine Mektovi is safe and effective for you. However, if you develop certain side effects, your doctor may pause your treatment or reduce your dosage. This depends on how severe the side effects are and how long it takes for the side effects to ease or go away.

    For this use, Mektovi is prescribed in combination with encorafenib (Braftovi). If your doctor recommends stopping Braftovi, you’ll also stop Mektovi.

    About taking Mektovi

    Below you’ll find information about key dosage issues.

    • When to take: You should take Mektovi twice daily, approximately 12 hours apart. For example, you can take one dose at 8 a.m. and one dose at 8 p.m. Taking Mektovi on a consistent schedule helps keep a steady level of the drug in your body. This helps the medication work effectively.
    • If you miss a dose: If you miss a dose of Mektovi, the instructions depend on how much time is left before your next dose is due. The typical dosage of Mektovi is one dose taken every 12 hours.
      • If you miss a dose of Mektovi and your next dose is due more than 6 hours away, go ahead and take the missed dose now.
      • If you miss a dose of Mektovi and your next dose is due within the next 6 hours, do not take the missed dose. Just take your regular dose at the next scheduled time.
    • If you vomit: If you vomit at any time after taking a dose of Mektovi, you should not take another dose to “make up” for it. Just continue taking your regular dose on your usual schedule.
    • Taking Mektovi with food: You can take Mektovi with or without food.
    • Crushing, splitting, or chewing Mektovi: The manufacturer of Mektovi does not offer guidance on whether it is safe to crush, split, or chew Mektovi tablets. So it’s best to swallow them whole. If you have trouble swallowing pills, talk with your doctor or pharmacist for advice.
    • Length of use: Mektovi is meant to be used as a long-term treatment. If you and your doctor determine that Mektovi is safe and effective for you, you’ll likely take it long term.
    • Length of time to work: Mektovi starts working shortly after you begin treatment. It may take several weeks or months before you and your doctor can determine if the medication is working effectively for you. Your doctor can give you details about when and how often they’ll monitor your condition. This typically involves tests or scans to check the size and location of your tumors.

    Overdose

    Overdose symptoms

    Using more than the recommended dosage of Mektovi can lead to serious side effects. Do not use more Mektovi than your doctor recommends.

    Do not use more Mektovi than your doctor recommends. For some drugs, doing so may lead to unwanted side effects or overdose.

    What to do in case you take too much Mektovi

    If you think you’ve taken too much of this drug, call your doctor. You can also call America’s Poison Centers at 800-222-1222 or use its online tool. However, if your symptoms are severe, call 911 or your local emergency number, or go to the nearest emergency room right away.

    Source link

    Respiratory Disorders Treatment Market Anticipated to Grow at

    Respiratory disorders pose significant health challenges worldwide, affecting millions of individuals and placing a substantial burden on healthcare systems. The respiratory disorders treatment market encompasses a diverse array of therapies, medications, and interventions aimed at managing conditions such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory infections. This article explores the latest advancements in the respiratory disorders treatment market, highlighting innovative therapies, emerging trends, and their impact on patients' respiratory health and quality of life.

    Respiratory Disorders Treatment market is estimated to attain a valuation of US$ 108 Bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6% during the forecast period, 2019-2027

    Get a Sample Copy of the Respiratory Disorders Treatment Market Research Report -www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39326&utm_source=openpr_amitugare&utm_medium=openpr

    The significant players operating in the global Respiratory Disorders Treatment market are

    Mylan N.V, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Sanofi, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries, CHIESI Farmaceutici S.p.A., Cipla, Vertex Pharmaceuticals Incorporated

    Key Advancements:

    Biologic Therapies: Biologic therapies, including monoclonal antibodies and targeted biologic agents, have revolutionized the treatment of severe asthma and COPD by targeting specific inflammatory pathways and immune mediators involved in airway inflammation and bronchoconstriction. Biologics such as omalizumab, mepolizumab, benralizumab, and dupilumab offer personalized treatment options for patients with uncontrolled asthma or eosinophilic COPD, reducing exacerbations, improving lung function, and enhancing quality of life.

    Precision Medicine: Advances in precision medicine and biomarker identification enable tailored treatment approaches based on individual patient characteristics, disease phenotypes, and genetic profiles. Biomarkers such as fractional exhaled nitric oxide (FeNO), blood eosinophil counts, and genetic markers help predict treatment response, guide medication selection, and optimize therapeutic outcomes in respiratory disorders, facilitating personalized care and precision medicine interventions.

    Digital Health Solutions: Digital health technologies, including mobile apps, wearable devices, and telemedicine platforms, empower patients with respiratory disorders to monitor symptoms, track lung function, and access remote healthcare services. Telemedicine consultations, virtual pulmonary rehabilitation programs, and home spirometry devices enhance patient engagement, improve access to care, and enable real-time monitoring of respiratory health parameters, promoting self-management and early intervention in respiratory exacerbations.

    Buy this Premium Research Report: - www.transparencymarketresearch.com/checkout.php?rep_id=39326&ltype=S

    Market Trends:

    Prevalence of Respiratory Diseases: The rising prevalence of respiratory diseases, including asthma, COPD, bronchiectasis, and respiratory infections, drives demand for respiratory disorder treatments worldwide. Environmental factors, air pollution, tobacco smoke exposure, and aging populations contribute to the increasing burden of respiratory disorders, necessitating effective management strategies, preventive measures, and innovative treatment options to address the growing healthcare challenges associated with respiratory health.

    Pharmacological Innovations: Pharmaceutical companies invest in research and development to introduce novel pharmacological agents, inhalation devices, and drug delivery technologies for respiratory disorder treatment. Long-acting bronchodilators, combination inhalers, triple therapy regimens, and fixed-dose combinations offer convenient, effective, and simplified treatment options for patients with asthma and COPD, enhancing treatment adherence, reducing medication burden, and optimizing disease control.

    Patient-Centered Care: Patient-centered care models, shared decision-making approaches, and multidisciplinary care teams prioritize patients' preferences, values, and treatment goals in respiratory disorder management. Collaborative care plans, patient education programs, and self-management strategies empower individuals with respiratory diseases to actively participate in their care, make informed treatment choices, and achieve optimal respiratory health outcomes, fostering partnerships between patients, caregivers, and healthcare providers.

    Market Segmentation -

    Disease

    Asthma

    Chronic Obstructive Pulmonary Disease (COPD)

    Lung Cancer

    Respiratory Tract Infection

    Allergic Rhinitis

    Cystic Fibrosis (CF)

    Others

    Drug Class

    Bronchodilators

    Corticosteroids

    Combination Drugs

    Antibiotics

    Target Therapy

    Immunotherapy

    CFTR

    Others

    Route of Administration

    Oral

    Nasal

    Injectable

    Distribution Channel

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    This Report lets you identify the opportunities in Respiratory Disorders Treatment Market by means of a region:

    North America (the United States, Canada, and Mexico)

    Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)

    Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))

    South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

    Key Features of the Respiratory Disorders Treatment Market Report: -

    ➤ Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.

    ➤ Examine the market opportunities for stakeholders by identifying higher growth sections.

    ➤ To study and analyze the global Respiratory Disorders Treatment industry status and forecast including key regions.

    ➤ An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.

    ➤ It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.

    ➤ It helps you make strategic business decisions and investment plans.

    More Trending Reports by Transparency Market Research -

    Brine Concentration Technology Market: www.globenewswire.com/en/news-release/2024/03/01/2838556/32656/en/Brine-Concentration-Technology-Market-to-Reach-USD-20-4-billion-Surging-at-a-CAGR-of-4-3-by-2031-Transparency-Market-Research-Inc.html

    Biopharmaceutical Fermentation Systems Market: www.globenewswire.com/en/news-release/2024/03/01/2838573/32656/en/Biopharmaceutical-Fermentation-Systems-Market-Projected-to-Reach-USD-52-6-billion-by-2031-with-a-CAGR-of-9-5-Report-by-Transparency-Market-Research-Inc.html

    About Us Transparency Market Research

    Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

    Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

    ???????????????????????????? ????????

    Transparency Market Research Inc.

    CORPORATE HEADQUARTER DOWNTOWN,

    1000 N. West Street,

    Suite 1200, Wilmington, Delaware 19801 USA

    Tel: +1-518-618-1030

    USA - Canada Toll Free: 866-552-3453

    This release was published on openPR.

    Source link

    AIRWAYS DISORDERS NETWORK

    Asthma and COPD Section

    Remodeling of airways and destruction of parenchyma by immune and inflammatory mechanisms are the leading cause of lung function decline in patients with chronic obstructive pulmonary disease (COPD). Type 2 inflammation has been recognized as an important phenotypic pathway in asthma. However, its role in COPD has been much less clear, which had been largely associated with innate immune response.1

    Activation of Interleukin (IL)-25, IL-33, thymic stromal lymphopoietin [TSLP] produces type 2 cytokines IL-4, IL-5, and IL-13, either by binding to ILC2 or by direct Th2 cells resulting in elevated eosinophils in sputum, lungs, and blood, as well as fractional exhaled nitric oxide.2 The combined inflammation from this pathway underpins the pathological changes seen in airway mucosa, causing mucous hypersecretion and hyperresponsiveness.

    Prior trials delineating the role of biologics, such as mepolizumab and benralizumab, showed variable results with possible benefit of add-on biologics on the annual COPD exacerbations among patients with eosinophilic phenotype of COPD.3

    More recently, the BOREAS trial evaluated the role of dupilumab as an add-on therapy for patients with type 2 inflammation-driven COPD established using blood eosinophil count of at least 300/mL at initial screening.4 Dupilumab is a human monoclonal antibody that blocks combined IL-4 and IL-13 pathways with a broader effect on the type 2 inflammation. It included patients with moderate to severe exacerbations despite maximal triple inhaler therapy with blood eosinophilia. Patients with asthma were excluded. This 52-week trial showed reduction in annual moderate to severe COPD exacerbations, sustained lung function improvement as measured by prebronchodilator FEV1, and improvement in patient-reported respiratory symptoms.4 Evaluation of sustainability of these results with therapy step-down approaches should be explored.

    Maria Azhar, MD, Section Fellow-in-Training

    Abdullah Alismail, PhD, RRT, FCCP, Section Member

    Raghav Gupta, MD, FCCP, Section Member

    References:

    1. Scanlon & McKenzie. 2012.

    2. Brussell, et al. 2013.

    3. Pavord, et al. 2017.

    4. Bhatt, et al. 2023.

    CHEST INFECTIONS & DISASTER RESPONSE NETWORK

    Disaster Response and Global Health Section

    Viral infections frequently cause acute respiratory failure requiring ICU admission. In the United States, influenza causes over 50,000 deaths annually and SARS-CoV2 resulted in 170,000 hospitalizations in December 2023 alone.1 2 RSV lacks precise incidence data due to inconsistent testing but is increasingly implicated in respiratory failure.

    Patients with underlying pulmonary comorbidities are at increased risk of severe infection. RSV induces bronchospasm and increases the risk for severe infection in patients with obstructive lung disease.3 Additionally, COPD patients with viral respiratory infections have higher rates of ICU admission, mechanical ventilation, and death compared with similar patients admitted for other etiologies.4

    Diagnosis typically is achieved with nasopharyngeal PCR swabs. Positive viral swabs correlate with higher ICU admission and ventilation rates in patients with COPD.4 Coinfection with multiple respiratory viruses leads to higher mortality rates and bacterial and fungal coinfection further increases morbidity and mortality.5

    Treatment includes respiratory support with noninvasive ventilation and high-flow nasal cannula, reducing the need for mechanical ventilation.6 Inhaled bronchodilators are particularly beneficial in patients with RSV infection.5 Oseltamivir reduces mortality in severe influenza cases, while remdesivir shows efficacy in SARS-CoV2 infection not requiring invasive ventilation.7 Severe SARS-CoV2 infection can be treated with immunomodulators. However, their availability is limited. Corticosteroids reduce mortality and mechanical ventilation in patients with SARS-CoV2; however, their use is associated with worse outcomes in influenza and RSV.7 8

    Vaccination remains crucial for prevention of severe disease. RSV vaccination, in addition to influenza and SARS-CoV2 immunization, presents an opportunity to reduce morbidity and mortality.

    Zein Kattih, MD, Section Fellow-in-Training

    Kathryn Hughes, MD

    Brian Tran, MD

    References:

    1. Troeger C, et al. Lancet Infect Dis. 2028;18(11):1191-1210.

    2. WHO COVID-19 Epidemilogical Update, 2024.

    3. Coussement J, et al. Chest. 2022;161(6):1475-1484.

    4. Mulpuru S, et al. Influenza Other Respir Viruses. 2022;16(6):1172-1182.

    5. Saura O, et al. Expert Rev Anti Infect Ther. 2022;20(12):1537-1550.

    6. Inglis R, Ayebale E, Shultz MJ. Curr Opin Crit Care. 2019;25(1):45-53.

    7. O'Driscoll LS, Martin-Loeches I. Semin Respir Crit Care Med. 2021;42(6):771-787.

    8. Bhimraj A, et al. Clin Inf Dis. 2022.

    CRITICAL CARE NETWORK

    Palliative & End-of-Life Section

    For providers caring for critically ill patients, navigating death and dying in the intensive care unit (ICU) with proficiency and empathy is essential. Approximately 20% of deaths in the United States occur during or shortly after a stay in the ICU and approximately 40% of ICU deaths involve withdrawal of artificial life support (WOALS) or compassionate extubation.

    This is a complex process that may involve advanced communication with family, expertise in mechanical ventilation, vasopressors, dialysis, and complex symptom management. Importantly, surrogate medical decision-making for a critically ill patient can be a challenging experience associated with anxiety and depression. How the team approaches WOALS can make a difference to both patients and decision-makers. Unfortunately, there is striking variation in practice and lack of guidance in navigating issues that arise at end-of-life in the ICU. One study of 2814 hospitals in the US with ICU beds found that 52% had intensivists while 48% did not.2 This highlights the importance of developing resources focusing on end-of-life care in the ICU setting regardless of the providers’ educational training.

    Important elements could include the role for protocol-based WOALS, use of oxygen, selection and dosing strategy of comfort-focused medications, establishing expectations, and addressing uncertainties. This would be meaningful in providing effective, ethical end-of-life care based on evidence-based strategies. While death may be unavoidable, a thoughtful approach can allow providers to bring dignity to the dying process and lessen the burden of an already difficult experience for patients and families alike.

    Angela L. Birdwell, DO, MA, Section Chair

    Nehan Sher, MD, Section Member

    References:

    1. Curtis JR, et al. Am J Respir Crit Care Med. 2012;186(7):587-592.

    2. Halpern NA, et al. Crit Care Med. 2019;47(4):517-525.

    SLEEP MEDICINE NETWORK

    Nonrespiratory Sleep Section

    Q: Are there interventions that can be readily implemented to improve sleep quality for hospitalized patients?

    Dr. Arora: A patient’s first night in the hospital is probably not the night to liberalize sleep; you’re still figuring out whether they’re stable. But by the second or third day, you should be questioning – do you need vitals at night? Do you need a 4 AM blood draw?

    We did an intervention called SIESTA that included both staff education about batching care and system-wide, electronic health record-based interventions to remind clinicians that as patients get better, you can deintensify their care. And we’re currently doing a randomized controlled trial of educating and empowering patients to ask their teams to help them get better sleep.

    Q: Does hospital sleep deprivation affect patients after discharge?

    Dr. Arora: Absolutely. “Posthospital syndrome” is the idea that 30 days after discharge, you’re vulnerable to getting readmitted – not because of the disease you came in with, but something else. And people who report sleep complaints in the hospital are more likely to be readmitted.

    When people are acutely sleep deprived, their blood pressure is higher. Their blood sugar is higher. Their cytokine response and immune function are blunted. And our work shows that sleep deficits from the hospital continue even when you go home. Fatigue becomes a very real issue. And when you’re super fatigued, are you going to want to do your physical therapy? Will you be able to take care of yourself? Will you be able to learn and understand your discharge instructions?

    We have such a huge gap to improve sleep. It’s of interest to people, but they are struggling with how to do it. And that’s where I think empowering frontline clinicians to take the lead is a great project for people to take on.

    Vineet Arora, MD, MAPP, is the Dean for Medical Education at the University of Chicago and an academic hospitalist who specializes in the quality, safety, and experience of care delivered to hospitalized adults.

    Alison Szabo, MD

    Lisa Wolfe, MD, Section Member

    THORACIC ONCOLOGY & CHEST PROCEDURES NETWORK

    Lung Cancer Section

    Lung cancer stands as the leading cause of cancer-related deaths globally, with its prevalence casting a long and challenging shadow. The most important risk factor for lung cancer is tobacco use, a relationship strongly substantiated by data. The impact of smoking cessation to reduce lung cancer incidence is underscored by the US Preventive Services Task Force (USPSTF), which mandates that smoking cessation services be an integral component of lung cancer screening programs.

    However, beneath the surface of this overarching concern lies a web of factors contributing to racial and ethnic disparities in smoking cessation. Cultural intricacies play a pivotal role in shaping these disparities. Despite higher instances of light or intermediate smoking, racially ethnic minority groups in the general population often face greater challenges in achieving smoking cessation, as highlighted by Bacio, et al (Addict Behav. 2014). Adding another layer to this complex scenario is the profound impact of sustained smoking during cancer treatment. Research suggests that for individuals diagnosed with lung cancer, smoking cessation can markedly boost treatment efficacy, reduce the risk of secondary tumors, and even double the chances of survival.1

    A study by Harris, et al. delving into the preferences of current smokers within a lung cancer screening setting uncovered noteworthy insights.2 White participants exhibited a fourfold greater likelihood of favoring a digital format for receiving smoking cessation information, while their Black counterparts expressed a preference for face-to-face support, phone assistance, or printed materials.

    Moreover, a meta-analysis conducted by Jabari, et al. sheds light on the efficacy of culturally targeted smoking interventions.3 This comprehensive review describes a dual-level approach to tailoring smoking cessation health interventions: surface and deep. Surface adaptations encompass elements like language and imagery, which aim to enhance the acceptability of interventions within specific communities. Simultaneously, deep-tailored elements identify culturally significant factors that can fundamentally influence the behavior of the target population. The findings of this meta-analysis reveal that the integration of culturally tailored components into standard interventions significantly enhances their efficacy in facilitating smoking cessation.

    In conclusion, sustained smoking cessation is a crucial element in combating the global burden of lung cancer. Recognizing the importance of individualized approaches in health care, it is imperative to tailor smoking cessation communications and interventions to diverse cultural influences and socioeconomic factors. Culturally tailored smoking cessation programs that account for nuances specific to each community have the potential to significantly enhance their effectiveness. This necessitates a shift towards individualized smoking cessation care, with a targeted focus on increasing cessation rates among racial and ethnic minority groups. In doing so, we take a step closer to a more equitable landscape in the battle against lung cancer.

    Stella Ogake, MD, FCCP, Section Member

    References:

    1. Dresler, et al. Lung Cancer. 2003.

    2. J Cancer Educ. 2018;33(5).

    3. Addiction. 2023.

    Source link

    COPD: A $10 Billion Threat to Canada's Healthcare System
    by 2030, Warns Country's Leading Lung Health Non-Profit

    Breathe Change Summons Public and Policy Leaders, Healthcare Professionals, Advocates
    and those Affected by Lung Disease to Amplify Their Voices in Support of Driving Progress

    LUNG HEALTH FOUNDATION LAUNCHES FIRST OF THREE LANDMARK POLICY FORUMS ON THURSDAY, MARCH 7 (CNW Group/Lung Health Foundation)LUNG HEALTH FOUNDATION LAUNCHES FIRST OF THREE LANDMARK POLICY FORUMS ON THURSDAY, MARCH 7 (CNW Group/Lung Health Foundation)

    LUNG HEALTH FOUNDATION LAUNCHES FIRST OF THREE LANDMARK POLICY FORUMS ON THURSDAY, MARCH 7 (CNW Group/Lung Health Foundation)

    TORONTO, March 4, 2024 /CNW/ - Chronic obstructive pulmonary disease (COPD) looms as a $10 billion healthcare crisis in Canada by 2030 and, according to the Lung Health Foundation ("LHF"), is poised to dismantle the Canadian healthcare system. LHF is the nation's leading non-profit organization dedicated to supporting and empowering individuals living with lung conditions across Canada.

    In response to this crisis, LHF launches "Breathe Change", a landmark series of three virtual policy forums beginning on Thursday, March 7 at 1 pm to 2:30 pm ET with Building Respiratory Resilience: Partnership for Improved Care & Funding in COPD.

    The inaugural forum will explore policy avenues to aid Canadians facing the most prevalent form of lung disease, scrutinize the impact of existing COPD interventions, probe access gaps in COPD programming and support mechanisms, champion the imperative role of spirometry in early COPD detection and treatment, and evaluate the influence of healthcare personnel on COPD care quality and outcomes. The session showcases the best-of-the-best in COPD and lung disease research, diagnosis and treatment modalities, and policy initiatives. Leading the expert COPD panel are Dr. Joshua Wald, Clinical Practice, Firestone Institute & Vice Co-Chair CTS COPD Assembly - COPD Steering Committee; Dr. Dawn Bowdish, Executive Director, Firestone Institute for Respiratory Health and Dr. Maya de Zoysa, Respirologist, West Nipissing General Hospital.

    The session welcomes participation from all Canadians, spanning public and policy spheres, healthcare practitioners, advocates, media and the millions impacted by COPD. For further details and to register for this free virtual event, visit bit.ly/BreatheChange

    "COPD in Canada remains a grossly underfunded lung condition, with only 1 in 5 afflicted individuals even receiving the necessary diagnosis and care," says LHF CEO Jessica Buckley. "COPD exacerbations currently rank as the number one cause of unplanned hospitalizations in Canada, creating a huge economic burden to our healthcare system. This serves as an urgent call-to-action for both federal and provincial health policy makers."

    "We Aim to Activate Change and Ignite a Transformative Shift in Perceptions of Lung Disease"

    Urgency underscores Buckley's message: "Through the largest series of policy forums on lung health in Canada, we aim to activate change and ignite a transformative shift in perceptions of lung disease, highlighting current policy efforts while propelling discussions toward new actionable solutions. The misconception that COPD solely stems from smoking must be dispelled, and our approach to caring for those impacted must evolve. Failing to do so risks compromising the quality of care for individuals dealing with this pervasive lung condition."

    Yet amid the challenges, Buckley says there is a beacon of hope for COPD sufferers. "The Lung Health Foundation wages a daily battle for the respiratory well-being of all Canadians as incidences of COPD escalate in tandem with wildfires, climate change, radon and deteriorating air quality."

    Attendees can also secure spots for upcoming lung health policy forums: Timely Triumph: Accelerating Lung Cancer Care – A Call to Action for Public and Policy Leaders (March 21) and Halt the Haze: A Strategic Approach to Ending Youth Vaping in Canada (April 18).

    The Breathtaking Truth about COPD

    • Over half (53%) of COPD sufferers reside in long-term care or senior homes.

    • 1 in 4 Canadians will develop COPD during their lifetimes. COPD, while chronic and progressive, remains treatable.

    • An additional 1 million Canadians with COPD languish undiagnosed and untreated.

    • COPD ranks as the 5th leading cause of mortality in Canada.

    • Nearly 900,000 Ontarians were living with COPD in 2019.

    • COPD endures neglect, with merely 1 in 5 afflicted individuals receiving diagnosis.

    • The current tally of Ontarians who are needlessly suffering is intolerable.

    • 1 in 10 COPD patients confront hospitalization due to exacerbations annually.

    • Annual emergency department visits for COPD exacerbations plague 1 in 20 COPD patients in Ontario.

    • While overall hospital admission rates have waned since 2002, COPD patient admissions have surged by 9.6% during the same period.

    Accessible Lung Health Foundation Support Programs and Resources Available 24/7

    For those navigating the labyrinth of lung disease, LHF offers an expansive array of disease-specific support programs and resources. Visitors to LHF's digital portal enjoy free access to Canada's premier real-time repository of lung disease management, education, and awareness initiatives. Among the many programs offered: the popular and in-demand virtual Fitness for Breath, Smoking and Vaping Cessation Quash App, My Lung Coach and Lung Health Hotline, where callers can talk directly to Certified Respiratory Educators about a gamut of lung health-related issues and challenges, including asthma, COPD, lung cancer, pneumonia, RSV, immunizations, inhalers, medications, breathing conditions, and indoor and outdoor air quality.

    About Lung Health Foundation

    The Lung Health Foundation is dedicated to improving lung health for all Canadians. Through a range of community initiatives, grass-roots educational programs, research, and advocacy, the organization elevates awareness and fosters a compassionate environment for those affected by lung conditions, including their caregivers. Building on the legacy of the Ontario Lung Association, which for over a century served as the recognized leader, voice, and primary resource in lung health, LHF has expanded its efforts nationally. The Lung Health Foundation works tirelessly to prevent lung disease, help people manage their lung conditions, and promote policy change to create a world where everyone can breathe with ease. The Lung Health Foundation encourages individuals to connect with its Lung Health Hotline for one-on-one advice from Certified Respiratory Educators. For assistance, call 1-888-344-LUNG, email [email protected], or engage in live chat at www.lunghealth.ca. Visit us on Instagram @lunghealthfoundation, Facebook at lunghealthfoundation/, and on X at @LungHealthFdn.

    SOURCE Lung Health Foundation

    CisionCision

    Cision

    View original content to download multimedia: www.newswire.ca/en/releases/archive/March2024/04/c3364.html

    Source link

    2023-2031] Computer and Gaming Glasses Market Current Trends and Growth  Opportunities

    Report Ocean has published a new report on the Mechanical Ventilator Market in diverse regions to produce a report with more than 250+pages. This market report is an excellent fusion of qualitative and quantitative data emphasizing major industry changes, business and competitor difficulties in gap analysis, and potential new possibilities in the Mechanical Ventilator Market.

    The Global Mechanical Ventilator Market has experienced significant growth, expanding from a valuation of $2.94 billion in 2019 to an estimated $12.54 billion by 2027. This report provides an in-depth analysis of the market dynamics, emphasizing the factors contributing to an impressive Compound Annual Growth Rate (CAGR) of 16.5% during the forecast period from 2020 to 2027. It covers the current market trends, growth drivers, challenges, and potential opportunities within the mechanical ventilator industry.

    Request To Download Free Sample of This Strategic Report @ reportocean.com/industry-verticals/sample-request?report_id=AMR1086

    Market Overview:

    Mechanical ventilators are critical life-support devices used in respiratory failures and other critical care conditions. They are essential in intensive care units (ICUs), emergency departments, and increasingly in home care settings. The demand for mechanical ventilators has surged, particularly highlighted by the COVID-19 pandemic, which significantly stressed healthcare systems worldwide.

    Mechanical ventilation is a lifesaving intervention for patients with respiratory disorders or respiratory failure. It is a form of breathing assistance in which a patient is connected to a machine through an endotracheal tube directly applied to the airway or non-invasive (NIV) mask. It is also employed as a diagnostic tool to measure static compliance of airway resistance and irregular functioning of respiratory system. Currently, intensive care and portable mechanical ventilators are the two most widely used ventilators available in the market.

    Growth Drivers and Opportunities:

    The market’s growth is primarily driven by the increasing incidence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and other acute respiratory infections. The COVID-19 pandemic has further underscored the vital role of mechanical ventilators in managing severe respiratory conditions, leading to a dramatic increase in demand.

    Download Free Sample of This Strategic Report with Industry Analysis @ reportocean.com/industry-verticals/sample-request?report_id=AMR1086

    Technological advancements in ventilator design, offering more patient-friendly, portable, and efficient devices, are propelling market growth. Additionally, the aging global population, susceptible to respiratory conditions requiring ventilatory support, and improvements in healthcare infrastructure across emerging economies present significant growth opportunities for the mechanical ventilator market.

    Increase in incidences of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and other lung disorders, and rise in number of accidental emergencies lead to substantial requirement of mechanical ventilators. In addition, growth in geriatric population prone to respiratory emergencies is one of the key drivers of the market. Moreover, technological innovations in respiratory care devices, namely, non-invasive ventilation technology and portable mechanical ventilators, further supplement the market growth.

    Challenges:

    Despite the optimistic growth outlook, the mechanical ventilator market faces several challenges. High costs associated with advanced ventilator systems can limit accessibility in low- and middle-income countries. Furthermore, the complexity of mechanical ventilators requires skilled healthcare professionals for operation and management, posing a challenge in regions facing healthcare workforce shortages.

    KEY BENEFITS FOR STAKEHOLDERS

    ? This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists in identifying prevailing market opportunities.
    ? An in-depth analysis of various regions is likely to provide a detailed understanding of the current trends to the stakeholders to formulate region-specific plans.
    ? Comprehensive analysis of factors that drive and restrain growth of the mechanical ventilator market are provided.
    ? Key regulatory guidelines for the mechanical ventilator market are critically dealt according to region.
    ? A deep dive analysis of various regions provides insights that would allow companies to strategically plan their business moves.

    To Get More Business Strategies For Request Free Sample Report @ reportocean.com/industry-verticals/sample-request?report_id=AMR1086

    Competitive Landscape:

    – Becton, Dickinson and Company
    – Carl Reiner GmbH
    – Draegerwerk AG & Co. KGaA
    – Getinge AB
    – General Electric Company (GE Healthcare)
    – Hamilton Medical AG
    – Koninklijke Philips N.V.
    – Medtronic Plc.
    – Mindray Medical International Limited
    – Smiths Group Plc.
    – Zoll Medical Corporation

    Factors Affecting the Growth of the Mechanical Ventilator Industry:

    Global Health Emergencies and Pandemics:

    The growth of the mechanical ventilator industry is heavily influenced by global health emergencies and pandemics, particularly during outbreaks of respiratory diseases such as COVID-19. During public health crises, there is an increased demand for mechanical ventilators to support patients with severe respiratory failure, including those with acute respiratory distress syndrome (ARDS) caused by infectious diseases. The COVID-19 pandemic, in particular, has highlighted the critical role of mechanical ventilators in treating severely ill patients and preventing mortality. The surge in demand for mechanical ventilators during the pandemic has led to increased production, innovation, and investment in the mechanical ventilator industry to meet the growing needs of healthcare systems worldwide. As the frequency and severity of global health emergencies continue to impact healthcare infrastructure and resource allocation, the demand for mechanical ventilators remains a key driver of growth in the industry.

    Technological Advancements and Innovation:

    Technological advancements and innovation drive growth and competitiveness in the mechanical ventilator industry. Manufacturers continuously invest in research and development to improve the design, functionality, and performance of mechanical ventilators, aiming to enhance patient outcomes, user experience, and safety. Innovations in ventilation modes, such as pressure-controlled ventilation, volume-controlled ventilation, and dual-mode ventilation, offer clinicians greater flexibility and customization in tailoring ventilation strategies to individual patient needs. Moreover, advancements in ventilator monitoring and control systems, including real-time data analytics, remote monitoring capabilities, and integration with electronic health records (EHRs), enable more precise and personalized ventilation management. Additionally, the development of portable and transport ventilators enhances the mobility and flexibility of mechanical ventilation in various healthcare settings, including ambulances, intensive care units (ICUs), and home care settings. As manufacturers continue to introduce innovative features and technologies to meet evolving clinical requirements and regulatory standards, the mechanical ventilator industry experiences sustained growth and technological advancement.

    For Further Information Regarding this Report: Request a Free Sample @ reportocean.com/industry-verticals/sample-request?report_id=AMR1086

    Regulatory Landscape and Quality Standards:

    The regulatory landscape and quality standards governing the manufacturing, distribution, and use of mechanical ventilators significantly impact the growth of the mechanical ventilator industry. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) establish guidelines and standards for the safety, efficacy, and quality of medical devices, including mechanical ventilators. Compliance with regulatory requirements, such as obtaining regulatory approvals or clearances, conducting clinical trials, and maintaining quality management systems, is essential for manufacturers to market their ventilators and ensure patient safety. Additionally, adherence to international quality standards, such as ISO 13485 certification for medical device quality management systems, demonstrates a commitment to quality and regulatory compliance. As regulatory requirements evolve and become more stringent, manufacturers invest in regulatory affairs and quality assurance processes to ensure compliance and market access for their mechanical ventilator products.

    Market Segmentation:

    The report segments the global mechanical ventilator market by product type (critical care ventilators, neonatal ventilators, portable ventilators, and others), mode (invasive and non-invasive), end-user (hospitals, ambulatory surgical centers, home care, and others), and geography. It provides a comprehensive analysis of each segment, detailing current market sizes, growth trends, and future projections.

    KEY MARKET SEGMENTS
    By Product Type
    – Intensive care unit/critical care
    – Transport/portable/ambulatory
    – Neonatal care

    By Component
    – Devices
    – Services

    By Mode
    – Non-invasive ventilation
    – Invasive ventilation

    By Age Group
    – Pediatric & neonatal
    – Adult
    – Geriatric

    By End User
    – Hospital and clinic
    – Home care
    – Ambulatory surgical center
    – Others

    By Region
    – North America
    o U.S.
    o Canada
    o Mexico
    – Europe
    o Germany
    o France
    o UK
    o Italy
    o Spain
    o Rest of Europe

    Get 30% Off On Various License Types When Buy Now At @ reportocean.com/industry-verticals/sample-request?report_id=AMR1086

    Table of Contents

    – Market Summary

    – Economic Impact Competition Analysis by Players

    – Production, Revenue (Value) by geographical segmentation

    – Market Size by Type and Application

    – Regional Market Status and Outlook

    – Market Analysis and Outlook

    – Market Forecast by Region, Type, and Application

    – Cost Investigation, Market Dynamics

    – Marketing Strategy comprehension, Distributors and Traders

    – Market Effect Factor Analysis

    – Research Finding/ Conclusion

    – Appendix

    – Continue……

    Some of the Key Aspects that the Report Analyses:

    • Which regions in Market are witnessing rise in investments in the supply chain networks?
    • Which regions have witnessed decline in consumer demand due to economic and political upheavals in Industry?
    • Which countries in Market seem to have benefitted from recent import and export policies?
    • Which are some the key geographies that are likely to emerge as lucrative markets?
    • What are some the sustainability trends impacting the logistics and supply chain dynamics in the Market?
    • What are some of the demographic and economic environments that create new demand in developing economies?
    • Which regions in Market are expected to lose shares due to pricing pressures?
    • Which regions leading players are expected to expand their footprints in the near future in Industry?
    • How are changing government regulations shaping business strategies and practices?

    Key Findings Market Reports:

    • Supply Chain Disruptions: Lockdowns, restrictions, and factory closures worldwide disrupted production and movement of goods, initially leading to reduced demand for this industry.
    • Shift in Demand: As consumer demand shifted, industry reports were increasingly used to transport essential goods such as medical supplies, PPE, pharmaceuticals, and groceries, while shipments of non-essential items declined.
    • Container Imbalances: Uneven trade flows and shipping disruptions caused imbalances in container availability, impacting pricing and availability across different regions.
    • Rising Shipping Costs: Increased demand for essential goods and disruptions in trade led to rising freight rates, affecting overall shipping costs and logistics.
    • Maintenance Challenges: Travel restrictions and lockdowns hindered maintenance activities for industry, potentially leading to longer-term maintenance challenges.
    • Supply Chain Resilience: Businesses recognized the need for greater supply chain resilience, leading to discussions and investments in robust container logistics and digital solutions.
    • Digital Adoption: The pandemic accelerated the adoption of digital solutions in logistics and supply chain management, including e-commerce and digital platforms for container booking and tracking.
    • Regulatory Impact: Governments implemented regulations and safety measures affecting shipping practices and container handling, impacting container operations.
    • Vaccine Transportation: Market played a vital role in transporting COVID-19 vaccines and related supplies, highlighting their importance in global health crises.
    • Supply Chain Strategies: Businesses reevaluated supply chain strategies, prioritizing risk mitigation and exploring alternatives for resilience against future disruptions.

    Request full Report :-  @ reportocean.com/industry-verticals/sample-request?report_id=AMR1086

    About Report Ocean:

    We are the best market research reports provider in the industry. Report Ocean is the world’s leading research company, known for its informative research reports. We are committed to providing our clients with both quantitative and qualitative research results. As a part of our global network and comprehensive industry coverage, we offer in-depth knowledge, allowing informed and strategic business conclusions to report. We utilize the most recent technology and analysis tools along with our own unique research models and years of expertise, which assist us to create necessary details and facts that exceed expectations.

    Get in Touch with Us:
    Report Ocean:
    Email[email protected]
    Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES
    Tel:+1 888 212 3539 (US – TOLL FREE)
    Website: reportocean.com

    Source link

    Published: Mon 4 Mar 2024, 6:00 AM

    Doctors in the UAE are highlighting at least a 10 per cent surge in patients seeking medical attention for persistent coughs.

    They said weather fluctuations commonly act as triggers for conditions such as asthma, allergies, and bronchitis, leading to an escalation in chronic cough during these changes.

    Medics explained chronic cough often stems from respiratory issues like asthma, Chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, bronchiectasis, and various other respiratory causes.

    Stay up to date with the latest news. Follow KT on WhatsApp Channels.

    Dr Jimmy Joseph, Specialist Internal Medicine and Diabetologist, Aster Clinic, International City said, “There is a surge in cases of cough. I get to see 8-10 patients daily in OPD with disturbing coughs lasting more than 10 days. We see persistent coughs greater than three weeks with nearly 20-30 per cent of daily cases. Persistent cough means when the cough lasts between three to eight weeks.”

    Dr Jimmy Joseph

    Dr Jimmy Joseph

    Acid reflux-induced cough

    Even Gastroesophageal reflux disease (GERD) is a condition where stomach acid regularly flows back into the esophagus, irritating the lining. When this acidic fluid reaches the throat and respiratory tract, it can lead to irritation and trigger a cough.

    “Causes include post viral/ post-infective cough, postnasal drip, GERD/ acid reflux, asthma, and smoking. Other causes include chronic bronchitis/COPD, Covid 19 and post-infection, ACE inhibitors (blood pressure medication), congestive heart failure, and lung cancer,” he added.

    Medics stressed the substantial increase in cough cases can be attributed significantly to the changing seasons, the flu, influenza, cold weather, rain, and dust.

    “Patients should approach a doctor when a cough lasts more than 7-10 days, a person loses weight rapidly, coughs out blood, has continuous fever, night sweats, chest pain, and shortness of breath. If your doctor prescribes an antibiotic, complete the full antibiotic course. Avoid OTC medications,” Joseph added.

    Dr Bassam Abdelmonem, consultant Emergency Care with Prime Hospital, also reiterated that they’ve recently observed an increased number of patients with chronic coughs.

    Dr Bassam Abdelmonem

    Dr Bassam Abdelmonem

    He said, “Around 10 per cent of patients visiting the Emergency Room (ER) present themselves with chronic cough. Weather changes are common asthma triggers; allergies and bronchitis then chronic cough will increase by these changes. Patients with chronic cough should seek medical advice when they have had a cough for more than three weeks persistently or they're losing weight for no reason. Other reasons include if one has a weakened immune system – for example, because of chemotherapy or diabetes.”

    Multiple underlying causes

    They emphasised determining the cause of chronic cough is crucial to effective treatment. In many cases, more than one underlying condition may cause a chronic cough.

    Healthcare professionals pointed out a persistent cough sometimes goes beyond being a mere inconvenience, as it can disrupt one’s sleep and lead to feelings of exhaustion. In more severe instances, chronic coughing may induce vomiting and dizziness, and even rarely result in rib fractures.

    Dr Zaid Mahdi Mohammed, Canadian Specialist Hospital Dubai, said, “The most common causes of chronic cough are postnasal drip, asthma, and acid reflux from the stomach. These three causes are responsible for up to 90 per cent of all cases of chronic cough. Honey and saltwater gargling, using a humidifier, or taking steam can be some of the effective home remedies.”

    Dr Zaid Mahdi Mohammed

    Dr Zaid Mahdi Mohammed

    ALSO READ:

    Source link